



UNIVERSITI PUTRA MALAYSIA

PROPHYLACTIC AND THERAPEUTIC EFFICACY OF DIETARY *Nigella sativa L.* SUPPLEMENTATION AGAINST HEPATOPATHY IN RATS INDUCED BY KAVALACTONE AND KAVALACTONE WITH ALCOHOL

MOHAMMED ABDULABBAS HASAN

FPV 2018 22



PROPHYLACTIC AND THERAPEUTIC EFFICACY OF DIETARY *Nigella sativa* L. SUPPLEMENTATION AGAINST HEPATOPATHY IN RATS INDUCED BY KAVALACTONE AND KAVALACTONE WITH ALCOHOL

MOHAMMED ABDULABBAS HASAN



**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfillment of the Requirements for the Degree of Doctor of Philosophy**

August 2018

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs, and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



DEDICATION

To my lovely country Iraq

To my parents, may God have mercy on them

*To my wife "Civil Engineer" Noralhuda, brother, sisters, lovely son "hasan" and
daughters "ruqayah and fatemah" whose encourage and gave me the power to
achieve my goal*

and

To all my sincere teachers, friends who boost me all those past years

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment
of the requirements for the degree of Doctor of Philosophy

PROPHYLACTIC AND THERAPEUTIC EFFICACY OF DIETARY *Nigella sativa* L. SUPPLEMENTATION AGAINST HEPATOPATHY IN RATS INDUCED BY KAVALACTONE AND KAVALACTONE WITH ALCOHOL

By

MOHAMMED ABDULABBAS HASAN

August 2018

Chairman : Professor Noordin Mohamed Mustapha, PhD
Faculty : Veterinary Medicine

Despite having potent psychoactive properties, the hepatotoxic effects of kavalactone (KL) is well documented. It has been banned in Europe and Canada with cautions and advisories by the US FDA. A study was designed to investigate the prophylactic and therapeutic efficacies of dietary *Nigella sativa* (NS) supplementation on the oral sub-acute and sub-chronic toxicity of 800 mg/kg KL with or without alcohol in rats. The idiosyncratic toxicity of KL appears to have an unclear risk-to-benefit ratio. Therefore, it is critical to identify and determine any possible adverse side effects of KL products that could potentially lead to toxicity especially when taken with alcohol. Seventy-two, female Sprague-Dawley rats, were divided randomly into two experimental studies, viz; prophylactic and therapeutic efficacy of NS supplementation against KL with or without alcohol. Rats were equally allotted into nine groups comprising six animals each, namely negative control (NCx1), positive control (NCx2), alcohol (EtOH), *Nigella sativa* (NS), kavalactone (KL) and alcohol plus kavalactone (EtOH+KL) and NS-preventing groups {(NS+KL), (NS+EtOH) and (NS+KL+EtOH)}. The other experimental trial is aimed at investigating the therapeutic effect of NS in treatment and reducing the hepatic lesion progression and establishment, wherein rats were equally assigned into nine groups comprising six animals each, namely control groups {(NCx1), (NCx2), (EtOH), (NS), (KL) and (EtOH+KL)} and NS-treatment groups {(NS+KL), (NS+EtOH) and (NS+KL+EtOH)}. Rats in the NS-preventive groups were given NS at doses of 100 mg/kg (b.w)/per day orally for three consecutive days prior to the onset of hepatotoxicity induction and then with the course of KL (alone or in combination) with EtOH as a prophylactic measure. On the other hand, those in the {(NS+KL), (NS+EtOH) and (NS+KL+EtOH)} treatment groups were given NS at the same dose, together with KL at 800 mg/kg/day (orally) (alone or in combination) with EtOH as a therapeutic measure. The sampling was done at weeks (W0), (W1),

(W2) and (W3) in both experiments as a sub-acute trial and also at weeks (W6), (W9), (W12) and (W14) as a sub-chronic study for both experiments. Exsanguinations were done following euthanasia followed by procurement of the liver at 3rd and 14th weeks post-treatment for the prophylactic and therapeutic study as sub-acute and sub-chronic trials.

Rats receiving KL plus EtOH showed the severest bodyweight changes, clinical signs (abnormal breathing, ataxia, lethargy, loss of appetite and incoordination), oxidative stress, and pathology of the liver (hepatocellular necrosis, hepatocellular hypertrophy with high proliferation of sER). Furthermore, dietary supplementation of NS for almost 14 weeks showed that NS exhibited an anti-oxidative stress effect in the liver as evidenced seen from the low ALT. In response to antioxidant enzymes, especially in preventing groups, an increase in SOD and GSH-Px indirectly has alleviated oxidative stress leading to a much lower MDA. The NS reduces the incidence of hepatopathy especially fatty degeneration, hepatomegaly, sER and peroxisome proliferation for more than 50%. This study demonstrated that dietary supplementation of NS at a dose of 100 mg/kg/day orally, significantly ($p < 0.01$) reduces serum lipid profile together with suppression of oxidative damage and therefore alleviates hepatopathy lesions. Ethanol potentiated the sedative and hypnotic activity of KL and markedly increased the toxicity whereas, KL toxicity is likely due to herbal drug interaction rather than direct liver toxicity from KL alone. Finally, NS is highly efficacious in abating oxidative stress and cellular damage in rats.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

KEBERKESANAN PROFILAKSIS DAN TERAPEUTIK PEMBERIAN SAMPINGAN *Nigella sativa* L. TERHADAP HEPATOPATI TERARUH ALKOHOL DENGAN DAN TANPA KAVALAKTON PADA TIKUS

Oleh

MOHAMMED ABDULABBAS HASAN

Ogos 2018

Pengerusi : Profesor Noordin Mohamed Mustapha, PhD
Fakulti : Perubatan Veterinar

Disebalik sifat psikoatif kuat, kesan hepatotoksik kavalakton (KL) amat diketahui. Ia telah diharamkan di Eropah dan Kanada dengan peringatan mudarat oleh FDA, Amerika Syarikat. Satu kajian telah direka untuk mengkaji keberkesanannya profilaksis dan terapeutik pemberian sampingan *Nigella sativa* (NS) terhadap ketoksikan oral sub-akut dan sub-kronik 800 mg/kg KL dengan dan atau tanpa alkohol. Ketoksikan idiosinkrasi KL didapati tiada mempunyai nisbah risiko ke manfaat yang jelas. Dengan itu, adalah kritikal untuk mengenalpasti dan menentukan kesan buruk hasilan KL yang berpotensi kepada ketoksikan terutama bersama alkohol. Sebanyak 72 ekor, tikus Sprague-Dawley betina dibahagikan dua kajian, profilaksis dan terapeutik keberkesanannya pemberian NS terhadap KL dengan atau tanpa alkohol. Tikus dibahagikan kepada Sembilan kumpulan mengandungi enam ekor setiap satu seperti berikut: kawalan negatif (NCx1), kawalan positif (NCx2), alkohol (EtOH), *Nigella sativa* (NS), kavalakton (KL) dan alkohol dengan kavalakton (EtOH+KL) and kumpulan pencegahan-NS {(NS+KL), (NS+EtOH) and (NS+KL+EtOH)}. Satu lagi kajian bertujuan mengkaji kesan terapeutik NS dalam merawat dan mengurangi kerosakan dan pengukuhan lesi hepar, dimana tikus dibahagikan kepada sembilan kumpulan mengandungi enam ekor setiap satu, yakni kawalan negatif (NCx1), kawalan positif (NCx2), alkohol (EtOH), *Nigella sativa* (NS), kavalakton (KL) and alkohol dengan kavalakton (EtOH+KL) and kumpulan terawat-NS {(NS+KL), (NS+EtOH) and (NS+KL+EtOH)}. Tikus dalam kumpulan NS-tercegah menerima NS pada kadar 100 mg/kg berat badan secara oral untuk tiga hari berturut sebelum permulaan aruhan dan kemudian dengan KL (sendirian atau gabungan) dengan EtOH sebagai langkah profilaksis. Sebaliknya, kumpulan rawatan lain {(NS+KL), (NS+EtOH) and (NS+KL+EtOH)} menerima NS pada kadar yang sama bersamaan dengan KL secara oral pada kadar 800 mg/kg (sendirian atau gabungan) dengan EtOH sebagai langkah terapeutik. Persampelan dilakukan pada minggu (W0), (W1),

(W2) dan (W3) pada kedua-dua kajian sebagai ujian sub-akut dan juga pada minggu (W6), (W9), (W12) dan (W14) sebagai ujian sub-kronik untuk kedua-dua kajian. Sembelihan disusuli dengan pengambilan hati pada minggu ketiga dan empat belas dibuat untuk kedua kajian.

Tikus yang menerima KL bersama EtOH mempunyai berat badan tertinggi, petanda klinikal (keabnormalan bernafas, ataksia, letargi, hilang selera dan ketidakselarasan), tegasan oksidatif dan patologi hepar (necrosis, hipertrofi dengan pemfoliferatan sER). Tambahan lagi, pemberian sampingan harian NS selama hampir 14 minggu menunjukkan bahawa NS mempamer kesan tegasan anti-oksidatif pada hati yang terbukti dengan ALT yang rendah. Sebagai gerakbalas kepada enzim anti-oksidaan, terutama pada kumpulan pencegahan, peningkatan SOD dan GSH-Px secara tak langsung telah meredakan tegasan oksidatif yang menjurus kepada MDA yang lebih rendah. Pemberian NS telah mengurangkan hampir 50% kesan hepatopati terutama penjanarosutan lemak, hepatomegali, pemfoliferatan sER dan peroksisom. Kajian ini menunjukkan bahawa pemberian NS pada dos 100 mg/kg/hari secara oral secara signifikan ($p<0.01$) merendahkan profil lipid serum bersamaan dengan penindasan kerosakan oksidatif dan dengan itu meredakan lesi hepatopati. Etanol telah memperkasa aktiviti sedative dan hypnosis KL dan dengan ketaranya meningkatkan ketoksisan dimana ketoksisan KL berkemungkinan akibat dari interaksi drug-herba daripada kerosakan langsung hati akibat KL sahaja. Akhir sekali, NS adalah amat mujarab dalam menangani tegasan oksidatif dan sel pada tikus.

ACKNOWLEDGEMENTS

In the name of Allah the Merciful

Alhamdulillah, all praise to Allah for his intensity and blessings in the performance of this letter.

Special appreciate goes to my supervisor, Prof. Dr. Noordin Mohamed Mustapha for his support, his patience and his mentorship. I would like to extend my utmost appreciation to my supervisor committee members, Assoc. Prof. Dr. Arifah Abdul Kadir and Assoc. Prof. Dr. Mohd Hezmee Mohd Noor for all their precious advices, guidance, collaboration, and mentorship. I couldn't have asked for a better committee and I am certainly would like to thank all of them for the constant support in progressing me from zero to hero. My research would not be possible if not for the assistance of my other people. I wish to express my gratitude to all working staff in the Department of Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia. Exceptional thanks are due to Dr. Mazlina Mazlan from our Department for her invaluable assistance and guides in performing the antioxidant enzymes assay.

Last, but not least, I would like to express my deep thanks and appreciation to my Idol, raw model and number one motivator, my wife Noralhuda Mohamed, since, this work would not have been possible without her continuous support and encouragement. May the Allah bless you all.

I certify that a Thesis Examination Committee has met on 17 August 2018 to conduct the final examination of Mohammed Abdulabbas Hasan on his thesis entitled "Prophylactic and Therapeutic Efficacy of Dietary *Nigella sativa* L. Supplementation Against Hepatopathy in Rats Induced by Kavalactone and Kavalactone with Alcohol" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Thesis Examination Committee were as follows:

Hazilawati binti Hamzah, PhD

Associate Professor

Faculty of Veterinary Medicine

Universiti Putra Malaysia

(Chairman)

Zainul Amiruddin bin Zakaria, PhD

Associate Professor

Faculty of Medicine and Health Sciences

Universiti Putra Malaysia

(Internal Examiner)

Md Sabri bin Mohd Yusoff, PhD

Associate Professor

Faculty of Veterinary Medicine

Universiti Putra Malaysia

(Internal Examiner)

Ekowati Handharyani, PhD

Associate Professor

Bogor Agricultural University

Indonesia

(External Examiner)



RUSLI HAJI ABDULLAH, PhD

Professor and Deputy Dean

School of Graduate Studies

Universiti Putra Malaysia

Date: 31 October 2018

This thesis was submitted to the Senate of the Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Noordin Mohamed Mustapha, PhD

Professor

Faculty of Veterinary Medicine

Universiti Putra Malaysia

(Chairman)

Arifah Abdul Kadir, PhD

Associate Professor

Faculty of Veterinary Medicine

Universiti Putra Malaysia

(Member)

Mohd Hezmee Mohd Noor, PhD

Associate Professor

Faculty of Veterinary Medicine

Universiti Putra Malaysia

(Member)

ROBIAH BINTI YUNUS, PhD

Professor and Dean

School of Graduate Studies

Universiti Putra Malaysia

Date:

Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software

Signature: _____

Date: _____

Name and Matric No: Mohammed Abdulabbas Hasan, GS40054

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) were adhered to.

Signature:

Name of Chairman
of Supervisory
Committee:

Professor Dr. Noordin Mohamed Mustapha

Signature:

Name of Member
of Supervisory
Committee:

Associate Professor Dr. Arifah Abdul Kadir

Signature:

Name of Member
of Supervisory
Committee:

Associate Professor Dr. Mohd Hezmee Mohd Noor

TABLE OF CONTENTS

| | Page |
|---|------|
| ABSTRACT | i |
| ABSTRAK | iii |
| ACKNOWLEDGEMENTS | v |
| APPROVAL | vi |
| DECLARATION | viii |
| LIST OF TABLES | xiv |
| LIST OF FIGURES | xvi |
| LIST OF ABBREVIATIONS | xx |
| | |
| CHAPTER | |
| 1 GENERAL INTRODUCTION | 1 |
| | |
| 2 LITERATURE REVIEW | 4 |
| 2.1 Oxidative stress | 4 |
| 2.1.1 Malondialdehyde (MDA) | 4 |
| 2.1.2 Superoxide dismutase (SOD) | 5 |
| 2.1.3 Glutathione Peroxidase (GSH-Px or G-Px) | 5 |
| 2.1.4 Glutathione | 5 |
| 2.2 Drug-induced Hepatotoxicity | 6 |
| 2.2.1 Kava Kava | 6 |
| 2.2.1.1 History, Properties, Preparation and Usage | 6 |
| 2.2.1.2 Kava as a Beverage in South Pacific | 7 |
| 2.2.1.3 Origins of Kava | 8 |
| 2.2.1.4 History and use of kava in the West | 8 |
| 2.2.1.5 Traditional preparation | 9 |
| 2.2.1.6 Modern preparation | 9 |
| 2.2.1.7 Safety | 10 |
| 2.2.1.8 Reports of prohibition | 10 |
| 2.2.1.9 Pharmacokinetics | 11 |
| 2.2.1.10 Biological Effects | 12 |
| 2.2.1.11 Adverse Effects | 12 |
| 2.2.1.12 Induction of Herb-drug Interactions and Kava-drug Interactions | 15 |
| 2.2.1.13 Possible mechanisms for kavalactones hepatotoxicity | 16 |
| 2.2.2 Ethyl Alcohol | 17 |
| 2.2.2.1 Alcoholic liver disease (ALD) | 17 |
| 2.2.2.2 Pathogenesis of Alcoholic Liver Disease: The Mechanisms of Liver Damage | 19 |
| 2.3 NS | 23 |
| 2.3.1 Synonym(s), Common names and Origin of the name | 23 |
| 2.3.2 Traditional uses of <i>N. sativa</i> | 24 |

| | | |
|----------|---|-----------|
| 2.3.3 | Chemical composition of <i>N. sativs</i> and its aqueous solution | 24 |
| 2.3.4 | Pharmacological properties of NS | 24 |
| 2.3.4.1 | Antioxidant activity | 24 |
| 2.3.4.2 | Anti-cancer activity | 25 |
| 2.3.4.3 | Immunomodulatory effect | 26 |
| 2.3.4.4 | Anti-fibrosis activity | 26 |
| 2.3.4.5 | Hepatoprotective activity of freshly prepared aqueous suspension of whloe NS seeds and/or its constituens | 26 |
| 2.3.4.6 | Mechanisms of hepatoprotective effect of <i>N. sativa</i> freshly prepared aqueous suspension | 28 |
| 3 | GENERAL MATERIALS AND METHODS | 29 |
| 3.1 | Materials | 29 |
| 3.1.1 | Animals and management | 29 |
| 3.1.2 | Chemicals and Drugs | 29 |
| 3.1.3 | Kava Kava (Kava, KL) | 30 |
| 3.1.4 | NS | 30 |
| 3.1.5 | Equipments and Tools | 30 |
| 3.1.6 | Apparatus | 30 |
| 3.2 | Methods | 31 |
| 3.2.1 | Preparation of NS solution | 31 |
| 3.2.2 | Preparation of KL | 31 |
| 3.2.3 | NS, alcohol and KL administration | 31 |
| 3.2.4 | Prophylactic role of NS in abating oxidative stress | 31 |
| 3.2.5 | KL Toxicity Assay | 32 |
| 3.2.6 | Experimental Design of main study | 32 |
| 3.2.6.1 | Prophylactic efficacy of NS in abating KL-induced toxicity | 32 |
| 3.2.6.2 | Therapeutic efficacy of NS in abating abating KL-induced toxicity | 33 |
| 3.2.7 | Sampling | 33 |
| 3.2.7.1 | Body weight, feed and water intake | 33 |
| 3.2.7.2 | Clinical signs | 33 |
| 3.2.7.3 | Blood and tissue sampling | 34 |
| 3.2.7.4 | Preparation of Serum and Plasma | 35 |
| 3.2.7.5 | Preparation of Blood Hemolysates | 37 |
| 3.2.7.6 | Preparation and Preservation of Tissue | 37 |
| 3.2.7.7 | Gross Pathology | 37 |
| 3.2.7.8 | Histopathology | 37 |
| 3.2.7.9 | Hematoxylin and Eosin (H&E) staining | 38 |
| 3.2.7.10 | Transmission Electron Microscopy | 38 |
| 3.2.7.11 | Lipid Peroxidation Biomarker Assay/ Estimation of Plasma Malondialdehyde (MDA) Concentration | 38 |
| 3.2.7.12 | Antioxidant biomarkers assay | 39 |
| 3.2.7.13 | Statistical Analysis | 40 |

| | | |
|----------|--|-----|
| 4 | PROPHYLACTIC EFFICACY OF DIETARY NS SUPPLEMENTATION AGAINST KL AND KL PLUS EtOH-INDUCED HEPATOPATHY IN RATS | 41 |
| 4.1 | Introduction | 41 |
| 4.2 | Materials and Methods | 42 |
| 4.3 | Results | 42 |
| 4.3.1 | Sub-acute prophylactic trial | 42 |
| 4.3.1.1 | Health status (Mortality and Clinical Observations) | 42 |
| 4.3.1.2 | Body weight | 44 |
| 4.3.1.3 | Liver weight | 45 |
| 4.3.1.4 | Relative liver weight | 46 |
| 4.3.1.5 | Feed intake | 46 |
| 4.3.1.6 | Water consumption | 47 |
| 4.3.1.7 | Biochemical analysis | 48 |
| 4.3.1.8 | Selected serum biochemical parameters | 51 |
| 4.3.1.9 | Pathological investigations | 53 |
| 4.3.2 | Sub-chronic prophylactic trial | 65 |
| 4.3.2.1 | Clinical observations | 65 |
| 4.3.2.2 | Body weight | 67 |
| 4.3.2.3 | Liver weight | 67 |
| 4.3.2.4 | Relative liver weight | 68 |
| 4.3.2.5 | Feed intake | 69 |
| 4.3.2.6 | Water consumption | 69 |
| 4.3.2.7 | Biochemical analysis | 71 |
| 4.3.2.8 | Selected serum biochemical parameters | 73 |
| 4.3.2.9 | Pathological Examinations/ Gross Pathology | 75 |
| 4.3.2.10 | Histopathological Evaluations and Lesion scoring for H & E Sections of Tissue | 78 |
| 4.3.2.11 | Ultrastructural analyses | 87 |
| 4.3.2.12 | Correlations Among Histopathological Lesions Score and Biochemical Parameters Like Health Status And Liver Somatic Index | 92 |
| 4.4 | Discussion | 94 |
| 5 | THERAPEUTIC EFFECTS OF NS SUPPLEMENTATION AGAINST KL-FED RATS EITHER ALONE OR IN COMBINATION WITH EtOH | 102 |
| 5.1 | Introduction | 102 |
| 5.2 | Materials and Methods | 103 |
| 5.3 | Results | 103 |
| 5.3.1 | Sub-acute therapeutic trial | 103 |
| 5.3.1.1 | Clinical Observations | 103 |
| 5.3.1.2 | Body weight | 103 |
| 5.3.1.3 | Liver weight | 104 |
| 5.3.1.4 | Relative liver weight | 105 |
| 5.3.1.5 | Feed intake | 106 |
| 5.3.1.6 | Water consumption | 106 |

| | | |
|-----------------------------|--|-----|
| 5.3.1.7 | Free Radicals Scavenger, Antioxidant Enzymes E- (SOD & GSH-Px) and Oxidative Stress Biomarker (MDA) | 108 |
| 5.3.1.8 | Selected serum biochemical parameters | 110 |
| 5.3.1.9 | Pathological investigations | 113 |
| 5.3.2 | Sub-chronic therapeutic trial | 118 |
| 5.3.2.1 | Clinical observations | 118 |
| 5.3.2.2 | Body weight | 118 |
| 5.3.2.3 | Liver weight | 119 |
| 5.3.2.4 | Relative liver weight | 120 |
| 5.3.2.5 | Feed intake | 120 |
| 5.3.2.6 | Water consumption | 121 |
| 5.3.2.7 | Biochemical analysis | 123 |
| 5.3.2.8 | Selected serum biochemical parameters | 125 |
| 5.3.2.9 | Pathological investigations/ Gross pathology | 127 |
| 5.3.2.10 | Histopathological Evaluations and Lesion Scoring for H & E Sections of Tissue | 128 |
| 5.3.2.11 | Ultrastructure | 133 |
| 5.3.2.12 | Correlation among histopathological lesions score and biochemical parameters, health status and somatic index of liver | 135 |
| 5.4 | Discussion | 137 |
| 6 | GENERAL DISCUSSION/ CONCLUSION AND FUTURE STUDIES | 143 |
| 6.1 | General Discussion | 143 |
| 6.2 | Conclusion | 146 |
| 6.3 | Future Work | 147 |
| REFERENCES | | 148 |
| APPENDICES | | 178 |
| BIODATA OF STUDENT | | 182 |
| LIST OF PUBLICATIONS | | 184 |

LIST OF TABLES

| Table | | Page |
|-------|--|------|
| 4.1 | The mean comparison among treatments for body weight (mean \pm SE) for prophylactic (sub-acute) study | 45 |
| 4.2 | The mean comparison among treatments for feed intake (mean \pm SE) for prophylactic (sub-acute) study | 47 |
| 4.3 | The mean comparison among treatments for water consumption (mean \pm SE) for prophylactic (sub-acute) study | 47 |
| 4.4 | Changes in body weight, absolute and relative liver weights, feed intake and water consumption (mean) \pm SE of rats and during the trial | 48 |
| 4.5 | Changes in lipid peroxidation, antioxidant and liver and kidney function enzymes (mean \pm SE) | 52 |
| 4.6 | Sub-acute lesion scoring for liver tissue obtained from NS-prophylactic groups and another treated groups | 64 |
| 4.7 | The mean comparison among treatments for body weight (mean \pm SE) for prophylactic (sub-chronic) study | 67 |
| 4.8 | The mean comparison among treatments for feed intake (mean \pm SE) for prophylactic (sub-chronic) study | 69 |
| 4.9 | The mean comparison among treatments for water consumption (mean \pm SE) for Prophylactic (sub-chronic) study | 70 |
| 4.10 | Changes in body weight, absolute and relative liver weights, feed and water intake (mean) \pm SE compared NCx for sub-chronic prophylactic trial | 70 |
| 4.11 | Changes in lipid peroxidation, antioxidant and liver and kidney function enzymes of experimental groups compared to NCx, (sub-chronic prophylactic trial) | 75 |
| 4.12 | Lesion scoring for liver tissue obtained from prophylactic sub-chronic trial | 85 |
| 4.13 | The correlations between all selected histopathological lesions at variable biochemical parameters, health status and somatic index at prophylactic study (sub-acute and sub-chronic) trials | 93 |
| 5.1 | The mean comparison among treatments for body weight (mean \pm SE) for therapeutic (sub-acute) study | 104 |

| | | |
|------|---|-----|
| 5.2 | The mean comparison among treatments for feed intake (mean \pm SE) for therapeutic (sub-acute) study | 106 |
| 5.3 | The mean comparison among treatments for water consumption (mean \pm SE) for therapeutic (sub-acute) study | 107 |
| 5.4 | Changes (%) in body weight, absolute and relative liver weights, feed and water intake (mean) \pm SE of NS, EtOH, KL-treated rats and NS-therapeutic groups | 107 |
| 5.5 | Changes in lipid peroxidation, antioxidant and liver and kidney function enzymes (mean \pm SE) of NS, EtOH, KL-treated rats and NS-treatment groups | 112 |
| 5.6 | Sub-acute lesion scoring for liver tissue obtained from NS-therapeutic groups and another treated groups | 117 |
| 5.7 | The mean comparison among treatments for body weight (mean \pm SE) for therapeutic (sub-chronic) study | 119 |
| 5.8 | The mean comparison among treatments for feed intake (mean \pm SE) for therapeutic (sub-chronic) study | 121 |
| 5.9 | The mean comparison among treatments for water consumption (mean \pm SE) for therapeutic (sub-chronic) study | 121 |
| 5.10 | Changes in body weight, absolute and relative liver weights, feed and water intake of treatment groups compared to NCx, for sub-chronic therapeutic trial | 122 |
| 5.11 | Changes in lipid peroxidation, antioxidant and liver and kidney enzymes (mean \pm SE) of treatment groups compared to NCx, for therapeutic sub-chronic trial | 126 |
| 5.12 | Lesion scoring for liver tissue obtained from therapeutic sub-chronic trial | 132 |
| 5.13 | The correlations between all selected histopathological lesions at variable biochemical parameters, health status and somatic index at therapeutic study (sub-acute and sub-chronic) trials | 136 |

LIST OF FIGURES

| Figure | Page |
|--|-------------|
| 2.1 Kava Kava (<i>Piper methysticum</i> Forst.) images obtained from (Lüde, 2005) | 7 |
| 2.2 Mechanisms by which ethanol consumption may lead to liver damage | 19 |
| 3.1 Flowchart representing the experimental design | 34 |
| 3.2 Schematic diagram depicting the blood and organ sample processing and analysis | 36 |
| 4.1 Photographs demonstrating the clinical observation throughout the sub-acute trial | 44 |
| 4.2 The mean of liver weight for all treatments at 3 rd week of prophylactic (sub-acute trial) against the time | 45 |
| 4.3 The mean of relative liver weight for all treatments at 3 rd week of prophylactic (sub-acute trial) against the time | 46 |
| 4.4 The concentration of SOD (u/ml) level of control and treated rats against time for prophylactic sub-acute trial | 49 |
| 4.5 The mean concentration of G-Px (U/g Hb) level of control and treated rats against time for prophylactic sub-acute trial | 50 |
| 4.6 The mean concentration of MDA (nmol/ml) level of control and treated rats against time for prophylactic sub-acute trial | 50 |
| 4.7 The mean concentration of ALT (U/L) level of control and treated rats against time for prophylactic sub-acute trial | 51 |
| 4.8 The mean concentration of CREA (umol/L) level of control and treated rats against time for prophylactic sub-acute trial | 52 |
| 4.9 Photograph illustrating the gross morphological changes of liver at prophylactic sub-acute trial | 54 |
| 4.10 Photomicrograph of liver sections at prophylactic sub-chronic trial | 63 |
| 4.11 Photographs demonstrating the clinical observation throughout the sub-chronic trial of prophylactic study | 66 |
| 4.12 The mean of liver weight for all treatments at week 3 (sub-acute) and week 14 (sub-chronic) against the time for prophylactic study | 68 |

| | | |
|------|---|-----|
| 4.13 | The mean of relative liver weight for all treatments at week 3 (sub-acute) and week 14 (sub-chronic) against the time | 68 |
| 4.14 | The mean SOD (u/ml) level of control and treated rats against time. Dashed black arrow represent sub-acute trial while, long black arrow represents sub-chronic trial | 72 |
| 4.15 | Graph plotting (mean ± SE) of G-Px (U/g Hb) level of control and treated rats against time. Dashed black arrow represent sub-acute trial while, long black arrow represents sub-chronic trial | 72 |
| 4.16 | The mean MDA (nmol/ml) level of control and treated rats against time. Dashed black arrow represent sub-acute trial while, long black arrow represents sub-chronic trial | 73 |
| 4.17 | The mean ALT (U/L) level of control and treated rats against time. Dashed black arrow represent sub-acute trial while, long black arrow represents sub-chronic trial | 74 |
| 4.18 | The mean CREA (umol/L) level of control and treated rats against time. Dashed black arrow represent sub-acute while, long black arrow represents sub-chronic trial | 74 |
| 4.19 | Photograph illustrating the gross morphological changes of liver at sub-chronic prophylactic trial | 77 |
| 4.20 | Photomicrograph of liver sections at sub-chronic prophylactic trial | 83 |
| 4.21 | Possible mechanisms for KAVA hepatotoxicity and interaction with EtOH that raised the possibility of adverse effects | 86 |
| 4.22 | Transmission electron micrographs of liver from (A) control & (B) NS groups at 14th week | 88 |
| 4.23 | Transmission electron micrographs of liver from (C) EtOH, (D) KL & (E) EtOH+KL groups at 14th week | 90 |
| 4.24 | Transmission electron micrographs of liver from (F) NS+EtOH, (G) NS+KL & (H) NS+EtOH+KL groups at 14th week | 91 |
| 5.1 | The mean of liver weight for all treatments at 3 rd week (therapeutic sub-acute trial) against the time | 105 |
| 5.2 | The mean of relative liver weight for all treatments at week 3 (sub-acute trial) against the time | 105 |
| 5.3 | The concentration of SOD (u/ml) level of control and treated rats against time for therapeutic sub-acute trial | 108 |

| | | |
|------|---|-----|
| 5.4 | The mean concentration of G-Px (U/g Hb) level of control and treated rats against time for therapeutic sub-acute trial | 109 |
| 5.5 | The mean concentration of MDA (nmol/ml) level of control and treated rats against time for therapeutic sub-acute trial | 110 |
| 5.6 | The mean concentration of ALT (U/L) level of control and treated rats against time for therapeutic sub-acute trial | 111 |
| 5.7 | The mean concentration of CREA (umol/L) level of control and treated rats against time for therapeutic sub-acute trial | 111 |
| 5.8 | Photograph illustrating the gross morphological changes of liver at sub-acute therapeutic trial | 113 |
| 5.9 | Photomicrograph of liver sections from NS-therapeutic groups (sub-acute trial) | 116 |
| 5.10 | The mean of liver weight for all treatments at 3 rd (sub-acute) and 14 th week (sub-chronic) | 119 |
| 5.11 | The mean of relative liver weight for all treatments at 3 rd (sub-acute) and 14 th week (sub-chronic) | 120 |
| 5.12 | The concentration of SOD (u/ml) level of control and treated rats against time. Dashed black arrow represent sub-acute trial while, long black arrow represents sub-chronic trial | 123 |
| 5.13 | The mean concentration of G-Px (U/g Hb) level of control and treated rats against time. Dashed black arrow represent sub-acute while, long black arrow represents sub-chronic trial | 124 |
| 5.14 | The mean concentration of MDA (nmol/ml) level of control and treated rats against time. Dashed black arrow represent sub-acute while, long black arrow represents sub-chronic trial | 124 |
| 5.15 | The mean concentration of ALT (U/L) level of groups against time. Dashed black arrow represents sub-acute while, long black arrow represents sub-chronic trial | 125 |
| 5.16 | The mean concentration of CREA (umol/L) level of control and treated rats against time. Dashed black arrow represent sub-acute while, long black arrow represents sub-chronic trial | 126 |
| 5.17 | Photograph of NS-therapeutic groups: (A) NS+Et, (B) NS+KL & (C) NS+EtOH+KL groups at sub-chronic therapeutic trial | 128 |
| 5.18 | Photomicrograph of liver sections at sub-chronic therapeutic trial | 131 |



LIST OF ABBREVIATIONS

| | |
|----------------|--|
| A _B | Absorbance of Blank Control |
| As | Absorbance of Sample |
| Ab | Absorbance of Standard Control |
| ALT | Alanine Aminotransferase |
| ALD | Alcoholic Liver Disease |
| ALDH | Aldehyde Dehydrogenase |
| ALP | Alkaline Phosphatase |
| V _s | Amount of Sample in The Extract |
| ACUC | Animal Care and Use Committee |
| AST | Aspartate Transaminase |
| BD | Bile Duct |
| BHT | Butylated Hydroxytoluene |
| CCL4 | Carbon Tetrachloride |
| CDC | Centers for Disease Control and Prevention |
| CV | Central Vein |
| Z ₃ | Centrilobular, Periacinar, Perivenous Zone |
| r | Correlation Coefficient |
| CREA | Creatinine |
| COX | Cyclooxygenase Enzyme |
| CYPs | Cytochromes P450 Isozymes |
| °C | Degree Celsius |
| DIW | Deionized Water |
| DNA | Deoxyribonucleic Acid |
| EtOH | Ethyl Alcohol |

| | |
|-----------------------------------|--|
| Ve | Final Volume of Extract |
| FDA | Food and Drug Administration |
| GGT | Gama-Glutamyl Transferase |
| GSH | Glutathione |
| G-P_X | Glutathione Peroxidase |
| GSR | Glutathione Reductase |
| GST | Glutathione S-Transferases |
| G | Grams |
| H&E | Hematoxylin and Eosin |
| Hb | Hemoglobin |
| t_{1/2} | Half-Life |
| HA | Hepatic Artery |
| HHP | Hepatocellular Hypertrophy |
| HN | Hepatocellular Necrosis |
| HDL | High-Density Lipoprotein |
| HPLC | High-Performance Liquid Chromatography |
| h | Hour |
| HCL | Hydrochlorous Acid |
| H₂O₂ | Hydrogen Peroxide |
| KL | Kavalactones (Alpha-Pyrones) |
| Kg | Kilogram |
| KCs | Kupffer Cells |
| LPS | Lipopolysaccharide |
| L | Liter |
| MDA | Malondialdehyde |
| pH | Measurement for Hydrogen Ion Concentration |

| | |
|-----------------|--|
| LD50 | Median Lethal Dose |
| HPO3 | Metaphosphoric Acid |
| μm | Micro Meter |
| μg | Microgram |
| μl | Microliter |
| Z_2 | Midzonal |
| mg | Milligrams |
| min | Minute |
| DPX | Mounting Media and Section Adhesive |
| NAPQI | N-acetyl-p-benzoquinone imine |
| NADPH | Nicotinamide Adenine Dinucleotide Phosphate |
| NS | <i>Nigella Sativa</i> |
| NP-SH | Non-Protein Thiol |
| GSSG | Oxidised Glutathione |
| O_2 | Oxygen |
| Z_1 | Periportal, Outer Zone |
| ONOO^- | Peroxynitrite |
| PBS | Phosphate Buffer Saline |
| PUFA | Polyunsaturated Fatty Acids |
| PV | Portal Vein |
| $B_{\Delta A}$ | Rate of Spontaneous Oxidation of Blank Control |
| $S_{\Delta A}$ | Rate of Spontaneous Oxidation of Sample |
| RNS | Reactive Nitrogen Species |
| RONs | Reactive Oxygen and Nitrogen Species |
| ROS | Reactive Oxygen Species |
| rER | Rough Endoplasmic Reticulum |

| | |
|---------------------------------|---|
| RPM | Round Per Minute |
| Se | Selenium |
| SS | Sinusoidal Space |
| sER | Smooth Endoplasmic Reticulum |
| NaOH | Sodium Hydroxide |
| Na ₂ WO ₄ | Sodium Tungstate |
| SI | Somatic Index |
| SPSS | Statistical package For the Social Sciences |
| H ₂ SO ₄ | Sulphuric Acid |
| SOD | Superoxide Dismutase |
| O ²⁻ . | Superoxide Molecules |
| TBHP | Tert-Butyl Hydroperoxide |
| TBA | Thiobarbituric Acid |
| TBARS | Thiobarbituric Acid Reactive Substances |
| TQ | Thymoquinone |
| TNF- α | Tissue Necrotizing Factor Alpha |
| ® | Trade Mark |
| TEM | Transmission Electron Microscopy |
| UPM | University Putra Malaysia |
| V _s | Volume of Plasma Sample |
| V _m | Volume of Total Reactive Mixture |
| v/v | Volume to Volume |
| W | Week |
| WHO | World Health Organization |
| w/v | Wright to Volume |
| XO | Xanthine Oxidase |

| | |
|------------|--|
| ANOVA | One-Way Analysis of Variance |
| TEP | 1,1,3,3-Tetraethoxypropane |
| $P < 0.05$ | Probability Values of Less Than Alpha 0.05 |



CHAPTER 1

GENERAL INTRODUCTION

Plants have been traditionally used to treat illnesses and diseases with varying degrees of success. It was only in the 20th century that the awareness on the side-effects of conventional drugs people has led to the search of traditional herbal remedies (Lüde, 2005). However, it should not be forgotten that the use of herbal plants is not without its very own untoward effect which may in severe cases lead to fulminant organ failure or death (Stickel et al., 2003). As natural products, herbs are mainly used as food additives and teas, however, manufactured herbal products are in the form of dietary supplements and drugs. The popularity of phytomedicine has been attributed to the perception that natural medicines are safe, gentle and cost-effective, as well as easily accessible and can be self-prescribed (Abebe, 2002). The danger of such assumption is self-medication of various herbal drugs without a validated medical advice.

Apart from the possible toxic of the parent herbal compounds, contamination (pesticides, heavy metals), their interaction with other drugs (e.g. *Hypericum perforatum*) and adulteration may contribute to toxic effects (De Smet, 2004). In short, injudicious use of phytomedicines could potentially cause serious detrimental effects (De Smet, 2004).

In order to establish an accurate and effective diagnosis of hepatotoxicity, a number of factors must be taken into account such as pattern recognition, anamnesis, awareness of the spectrum of herbal liver injury and botanic identification (Chitturi et al., 2000). Sometimes the hepatotoxic effect does not originate from the intake of a single botanical, but from the combination with other drugs. These interactions may occur through the induction of CYPs (like CYP3A4 or CYP2E1) by other drugs or alcohol, which could lead to enhanced production of toxic herbal metabolites (Stedman, 2002). Conversely, herbal components may also act by inhibiting CYPs, thus eventually causing an accumulation of concomitantly taken drugs. It was demonstrated in an *in vitro* study, that kava, garlic, Ginkgo biloba, and St. John's wort inhibited CYP 2C9, 2C19 and 3A4 (Zou et al., 2002). The occurrence of these interactions are not only limited via CYPs, but may occur via other pathways as well such as, the renal system (licorice–spironolactone), the immune system (Echinacea–corticosteroids, cyclosporine), the cardiac system (herbs containing cardiac glycosides–digoxin), and the clotting system (garlic, ginger, ginkgo–warfarin) (Miller, 1998; Lüde, 2005).

Problem Statement

In many countries mostly those within the Pacific Ocean and Micronesia, kava (*Piper methysticum*, KL) tinctures, extract capsules, teas and dried powders continue to be sold in health food stores, local markets, and kava "cafes" despite a consumer advisory issued by the Food and Drug Administration (FDA), concerning the potential hepatotoxicity of kava products. Therefore, it is critical to identify and determine any possible adverse side effects of KL products that could potentially lead to toxicity especially when taken with other substances like alcohol. Between 1990 and 2001, there were 82 case reports of alleged KL associated liver toxicity and deaths among patients consuming KL extract preparations were documented.

Likewise, in the past few years, about 35 cases of severe liver toxicity associated with KL intake have been reported in Europe and the US, with the occurrence of severe hepatic toxicity possibly related with the consumption of products containing kava. Until this day, KL is still used in religious practices and is of social and economic importance has in religious, social and economic life for too many of the Pacific Island communities. Thus, owing to quite extensive use spilling over beyond the Pacific Ocean and Micronesia, a database on its safety in combination with other compounds and an effective antidote is necessary.

Justifications of the study

One of the reasons for choosing kava in our study was because of its widespread use and popularity, with the general belief that it is safe, an effective anxiolytic, reliable, non-toxic, easily available and affordable, as compared to its synthetic chemical counterparts such as, Valium (diazepam), Xanax (alprazolam), Klonopin (clonazepam), and Ativan (lorazepam). However, there is a paucity of information and literature regarding the hepatotoxic effects of kava, and the hepatotoxicity pathway. Therefore, this study attempted to investigate the hepatotoxic effects of this popular drug. In same time we justify the using of alcohol with Kava in our study by: "Synthetic anxiety drugs such as, Xanax, Valium, Klonopin cannot be consumed with alcohol, as these drugs contain a black-box warning against use with alcohol, as it can be dangerous and potentially fatal. However, kava is widely used among alcoholics because of the belief that it is a "natural" safe alternative to synthetic drugs, and users feel that they can enjoy the benefits of mood alteration, without experiencing any adverse side effects".

On the other hand, we used NS seeds, as it has been recorded in literature that, it has strong and effective hepatoprotective effects, and possesses antioxidant and antifibrotic properties, and is known to be natural, affordable and very safe, even for long time use.

Hypothesis, Aim and Objectives

Based on documented evidence, it is hypothesised that long-term administration of whole black seeds can provide stronger hepatoprotective activity against KL-induced hepatopathy and alleviated extremely toxicity after combined with EtOH (EtOH+KL) via the anti-oxidative pathway.

Thus, the study is undertaken with the aim of paving an insight into the cellular mechanisms of toxicity of kava and mechanisms of kava toxicity alleviation by NS with the following objectives, to:

- i. to investigate the prophylactic and therapeutic efficacies of dietary *Nigella sativa* (NS) supplementation on the oral sub-(acute and chronic) toxicity induced by Kava-Kava.
- ii. to analyze the possible protective pathway of NS in abating KL-induced hepatotoxicity in rats.
- iii. to assess the extent of KL-induced hepatic damage in rats given KL with or without alcohol supplementation.
- iv. to determine the changes in detoxifying enzymes, anti-oxidant and peroxidation status in rats receiving KL with or without alcohol supplementation.

REFERENCES

- Abdel-Wahhab, M. A., & Aly, S. E. (2005). Antioxidant property of *Nigella sativa* (black cumin) and *Syzygium aromaticum* (clove) in rats during aflatoxicosis. *Journal of Applied Toxicology*, 25(3), 218–223.
- Abdollahi, M., Moridani, M. Y., Aruoma, O. I., & Mostafalou, S. (2014). Oxidative stress in aging. *Oxidative Medicine and Cellular Longevity*, 2014, 876834.
- Abebe, W. (2002). Herbal medication: potential for adverse interactions with analgesic drugs. *Journal of Clinical Pharmacy and Therapeutics*, 27(6), 391–401.
- Aboul-Ela, E. I. (2002). Cytogenetic studies on *Nigella sativa* seeds extract and thymoquinone on mouse cells infected with schistosomiasis using karyotyping. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, 516(1), 11–17.
- Advisory, C. (2002). Kava-containing dietary supplements may be associated with severe liver injury. *Center for Food Safety and Applied Nutrition, US Food and Drug Administration*.
- Ahmad, A., Husain, A., Mujeeb, M., Khan, S. A., Najmi, A. K., Siddique, N. A., & Damanhouri, Zoheir, O. (2013). A review on therapeutic potential of *Nigella sativa*: A miracle herb. *Asian Pacific Journal of Tropical Biomedicine*, 3(5), 337–352.
- Ait Mbarek, L., Ait Mouse, H., Elabbadi, N., Bensalah, M., Gamouh, A., Aboufatima, R., ... Dalal, A. (2007). Anti-tumor properties of blackseed (*Nigella sativa* L.) extracts. *Brazilian Journal of Medical and Biological Research*, 40(6), 839–847.
- Al-Ghamdi, M. S. (2003). Protective effect of *Nigella sativa* seeds against carbon tetrachloride-induced liver damage. *The American Journal of Chinese Medicine*, 31(5), 721–728.
- Al-Gharably, N. M., Badary, O. A., Nagi, M. N., Al-Shabanah, O. A., Al-Sawaf, H. A., Al-Rikabi, A. C., & Al-Bekairi, A. M. (1997). Protective Effect of Thymoquinone Against Carbon Tetra-Chloride-Induced Hepatotoxicity in Mice. *Research Communications in Pharmacology and Toxicology*, 2, 41–50.
- Al-okaily, B. N., Mohammed, R. S., Al-Mzain, K. A., & Khudair, K. K. (2012). Effect of flavonoids extracted from Black Cumin (*Nigella sativa*) and vitamin E in ameliorating hepatic damage induced by sodium nitrate in adult male rats. In *Proceeding of the Eleventh Veterinary Scientific Conference* (Vol. 172, p. 181).
- Al-Rowais, N. A. (2002). Herbal medicine in the treatment of diabetes mellitus. *Saudi Medical Journal*, 23(11), 1327–1331.

- Albano, E. (2006). Alcohol, oxidative stress and free radical damage. *Proceedings of the Nutrition Society*, 65(3), 278–290.
- Albano, E. (2008). Oxidative mechanisms in the pathogenesis of alcoholic liver disease. *Molecular Aspects of Medicine*, 29(1), 9–16.
- Alenzi, F. Q., El-Bolkiny, Y. E.-S., & Salem, M. L. (2010). Protective effects of *Nigella sativa* oil and thymoquinone against toxicity induced by the anticancer drug cyclophosphamide. *British Journal of Biomedical Science*, 67(1), 20–28.
- Ali, B. H., & Blunden, G. (2003). Pharmacological and toxicological properties of *Nigella sativa*. *Phytotherapy Research*, 17(4), 299–305.
- Allen, J., & Bradley, R. D. (2011). Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. *The Journal of Alternative and Complementary Medicine*, 17(9), 827–833.
- Almdal, T. P., & Sørensen, T. I. A. (1991). Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. *Hepatology*, 13(4), 650–655.
- Almeida, J. C., & Grimsley, E. W. (1996). Coma from the health food store. *Annals of Internal Medicine*, 125(11), 940–941.
- Amacher, D. E., Schomaker, S. J., & Burkhardt, J. E. (1998). The relationship among microsomal enzyme induction, liver weight and histological change in rat toxicology studies. *Food and Chemical Toxicology*, 36(9–10), 831–839.
- Amorim, M. F. D., Diniz, M. F. F. M., Araújo, M. S. T., Pita, J. C. L. R., Dantas, J. G., Ramalho, J. A., & Xavier, Aline L., O. (2007). The controversial role of kava (*Piper methysticum* G. Foster) an anxiolytic herb, on toxic hepatitis. *Revista Brasileira de Farmacognosia*, 17(3), 448–454.
- Amorim, M. de F. D. de, Amorim, W. P. D. de, Duques, P., Amorim, P. D. de, & Vasconcelos, J. R. de. (2005). Flutamide-induced hepatotoxicity during treatment of acne: a case report. *Anais Brasileiros de Dermatologia*, 80(4), 381–384.
- Anke, J., Fu, S., & Ramzan, I. (2006). Kavalactones fail to inhibit alcohol dehydrogenase in vitro. *Phytomedicine*, 13(3), 192–195.
- Anke, J., & Ramzan, I. (2004a). Kava Hepatotoxicity: Are we any closer to the truth? *Planta Medica*, 70(3), 193–196.
- Anke, J., & Ramzan, I. (2004b). Pharmacokinetic and pharmacodynamic drug interactions with Kava (*Piper methysticum* Forst. f.). *Journal of Ethnopharmacology*, 93(2–3), 153–160.

- Arteel, G. E. (2003). Oxidants and antioxidants in alcohol-induced liver disease. *Gastroenterology*, 124(3), 778–790.
- Arteel, G., Marsano, L., Mendez, C., Bentley, F., & McClain, C. J. (2003). Advances in alcoholic liver disease. *Best Practice & Research Clinical Gastroenterology*, 17(4), 625–647.
- Ayala, A., Muñoz, M. F., & Argüelles, S. (2014). Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. *Oxidative Medicine and Cellular Longevity*, 2014.
- Ayoub, M. M., El-Far, A. H., Taha, N. M., Korshom, M. A., Mandour, A. A., Abdel-Hamid, H. S., & El-Neweshy, M. O. (2011). The biochemical protective role of some herbs against aflatoxicosis in ducklings: I. Turmeric. *Zootechnie*, 55(40), 150–159.
- Badary, O. A. (1999). Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. *Journal of Ethnopharmacology*, 67(2), 135–142.
- Badary, O. A., Al-Shabanah, O. A., Nagi, M. N., Al-Rikabi, A. C., & Elmazar, M. M. (1999). Inhibition of benzo (a) pyrene-induced forestomach carcinogenesis in mice by thymoquinone. *European Journal of Cancer Prevention: The Official Journal of the European Cancer Prevention Organisation (ECP)*, 8(5), 435–440.
- Badary, O. A., & Gamal El-Din, A. (2001). Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis. *Cancer Detection and Prevention*, 25(4), 362–368.
- Badary, O. A., Taha, R. A., Gamal El-Din, A. M., & Abdel-Wahab, M. H. (2003). Thymoquinone is a potent superoxide anion scavenger. *Drug and Chemical Toxicology*, 26(2), 87–98.
- Bai, T., Lian, L.-H., Wu, Y.-L., Wan, Y., & Nan, J.-X. (2013). Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells. *International Immunopharmacology*, 15(2), 275–281.
- Bailey, S. M., & Cunningham, C. C. (2002). Contribution of mitochondria to oxidative stress associated with alcoholic liver disease. *Free Radical Biology and Medicine*, 32(1), 11–16.
- Baraona, E., Leo, M. A., Borowsky, S. A., & Lieber, C. S. (1977). Pathogenesis of alcohol-induced accumulation of protein in the liver. *The Journal of Clinical Investigation*, 60(3), 546–554.

- Barbacanne, M.-A., Margeat, E., Arnal, J.-F., Nepveu, F., & Souchard, J.-P. (1999). Superoxide release by confluent endothelial cells, an electron spin resonance (ESR) study. *Journal de Chimie Physique et de Physico-Chimie Biologique*, 96(1), 85–92.
- Bardag-Gorce, F., Yuan, Q. X., Li, J., French, B. A., Fang, C., Ingelman-Sundberg, M., & French, S. W. (2000). The effect of ethanol-induced cytochrome p4502E1 on the inhibition of proteasome activity by alcohol. *Biochemical and Biophysical Research Communications*, 279(1), 23–29.
- Barsky, A. J., Saintfort, R., Rogers, M. P., & Borus, J. F. (2002). Nonspecific medication side effects and the nocebo phenomenon. *Jama*, 287(5), 622–627.
- Baynes, J., & Dominiczak, M. H. (2014). *Medical Biochemistry* (4th Editio). Elsevier Health Sciences.
- Beckman, J. S. (1996). The physiological and pathological chemistry of nitric oxide. *The Journal of Physiology*, 271(5), C1424–C1437 .
- Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., & Freeman, B. A. (1990). Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proceedings of the National Academy of Sciences*, 87(4), 1620–1624.
- Belló-Klein, A., Khaper, N., Llesuy, S., Vassallo, D. V., & Pantos, C. (2014). Oxidative stress and antioxidant strategies in cardiovascular disease. *Oxidative Medicine and Cellular Longevity*, 2014.
- Benhaddou-Andaloussi, A., Martineau, L. C., Vallerand, D., Haddad, Y., Afshar, A., Settaf, A., & Haddad, P. S. (2010). Multiple molecular targets underlie the antidiabetic effect of Nigella sativa seed extract in skeletal muscle, adipocyte and liver cells. *Diabetes, Obesity and Metabolism*, 12(2), 148–157.
- Berk, M., Ng, F., Dean, O., Dodd, S., & Bush, A. I. (2008). Glutathione: a novel treatment target in psychiatry. *Trends in Pharmacological Sciences*, 29(7), 346–351.
- Bilzer, M., Roggel, F., & Gerbes, A. L. (2006). Role of Kupffer cells in host defense and liver disease. *Liver International*, 26(10), 1175–1186.
- Bode, Ckv., Kugler, V., & Bode, J. C. (1987). Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. *Journal of Hepatology*, 4(1), 8–14.
- Bonfanti, P., Landonio, S., Ricci, E., Martinelli, C., Fortuna, P., Faggion, I., ... others. (2001). Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, 27(3), 316–318.

- Borza, C., Balint, G. S., Andoni, M., & Butur, M. (2013). Implications of oxidative stress in the pathogenesis of diabetic neuropathy. *Journal of Food, Agriculture & Environment*, 11(1), 51–53.
- Boskabady, M. H., Javan, H., Sajady, M., & Rakhshandeh, H. (2007). The possible prophylactic effect of Nigella sativa seed extract in asthmatic patients. *Fundamental & Clinical Pharmacology*, 21(5), 559–566.
- Brauer, R. B., Pfab, R., Becker, K., Berger, H., & Stangl, M. (2001). Fulminantes leberversagen nach einnahme des pflanzlichen heilmittels kava-kava. *Z Gastroenterol*, 39(491), P30.
- Bressler, R. (2005). Interactions between Kava and prescription medications. *Geriatrics*, 60(9), 24–25.
- Bujanda, L. (2000). The effects of alcohol consumption upon the gastrointestinal tract. *The American Journal of Gastroenterology*, 95(12), 3374–3382.
- Bujanda, L., Palacios, A., Silvarino, R., Sanchez, A., & Munoz, C. (2002). Kava-induced acute icteric hepatitis. *Gastroenterología Y Hepatología*, 25(6), 434.
- Burits, M., & Bucar, F. (2000). Antioxidant activity of Nigella sativa essential oil. *Phytotherapy Research*, 14(5), 323–328.
- Butura, A. (2008). *Drug and alcohol induced hepatotoxicity*. *Pharmacogenetics*. Institutionen för fysiologi och farmakologi/Department of Physiology and Pharmacology.
- Cai, Y., Wang, H., Xiao, Y., Ren, J., & Others. (2005). Altered expression of cytochrome P450 and possible correlation with preneo plastic changes in early stage of rat hepatocarcinogenesis. *Acta Pharmacologica Sinica*, 26(6), 737–744.
- Cairney, S., Clough, A. R., Maruff, P., Collie, A., Currie, B. J., & Currie, J. (2003). Saccade and cognitive function in chronic kava users. *Neuropsychopharmacology*, 28(2), 389.
- Cairney, S., Maruff, P., & Clough, A. R. (2002). The neurobehavioural effects of kava. *Australian and New Zealand Journal of Psychiatry*, 36(5), 657–662.
- Calviño, J., Lens, X. M., Romero, R., & Sánchez-Guisande, D. (2000). Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension. *Nephrology Dialysis Transplantation*, 15(1), 82–86.
- Casini, A., Ceni, E., Salzano, R., Biondi, P., Parola, M., & Galli, A., et al, . (1997). Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. *Hepatology*, 25(2), 361–367.

- Cederbaum, A. I., Wu, D., Mari, M., & Bai, J. (2001). CYP2E1-dependent toxicity and oxidative stress in HepG2 cells 1, 2. *Free Radical Biology and Medicine*, 31(12), 1539–1543.
- Chitturi, S., & Farrell, G. C. (2000). Herbal hepatotoxicity: an expanding but poorly defined problem. *Journal of Gastroenterology and Hepatology*, 15(10), 1093–1099.
- Clark, J. D., Gebhart, G. F., Gonder, J. C., Keeling, M. E., & Kohn, D. F. (1997). The 1996 guide for the care and use of laboratory animals. *ILAR Journal*, 38(1), 41–48.
- Clayton, N. P., Yoshizawa, K., Kissling, G. E., Burka, L. T., Chan, P.-C., & Nyska, A. (2007). Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. *Experimental and Toxicologic Pathology*, 58(4), 223–236.
- Clouatre, D. L. (2004). Kava kava: examining new reports of toxicity. *Toxicology Letters*, 150(1), 85–96.
- Clough, A. R., Bailie, R. S., & Currie, B. (2003). Liver function test abnormalities in users of aqueous kava extracts. *Journal of Toxicology: Clinical Toxicology*, 41(6), 821–829.
- Clough, A. R., Jacups, S. P., Wang, Z., Burns, C. B., Bailie, R. S., Cairney, S. J., ... Currie, B. J. (2003). Health effects of kava use in an eastern Arnhem Land Aboriginal community. *Internal Medicine Journal*, 33(8), 336–340.
- Côté, C. S., Kor, C., Cohen, J., & Auclair, K. (2004). Composition and biological activity of traditional and commercial kava extracts. *Biochemical and Biophysical Research Communications*, 322(1), 147–152.
- Currie, B. J., & Clough, A. R. (2003). Kava hepatotoxicity with Western herbal products: does it occur with traditional kava use? *Med J Aust.*, 178(9), 421–422.
- Daba, M. H., & Abdel-Rahman, M. S. (1998). Hepatoprotective activity of thymoquinone in isolated rat hepatocytes. *Toxicology Letters*, 95(1), 23–29.
- Darakshan, S., Pour, A. B., Colagar, A. H., & Sisakhtnezhad, S. (2015). Thymoquinone and its therapeutic potentials. *Pharmacological Research*, 95, 138–158.
- Datta, A. K., Saha, A., Bhattacharya, A., Mandal, A., Paul, R., & Sengupta, S. (2012). Black cumin (*Nigella sativa* L.)--A review. *J Plant Dev Sci*, 4(1), 1–43.
- Davis, R. I., & Brown, J. F. (1999). Kava (*Piper methysticum*) in the South Pacific. *Canberra: ACIAR Technical Reports*, 46.

- Davison, C. (1927). Hawaiian medicine. *The Queen's Hospital Bulletin with Palama Clinic Section*, 4(3), 2–5.
- Day, C. P., & James, O. F. W. (1998). Steatohepatitis: a tale of two “hits”? *Gastroenterology*, 114(4), 842–845.
- De Abajo, F. J., Montero, D., Madurga, M., & Rodríguez, L. A. G. (2004). Acute and clinically relevant drug-induced liver injury: a population based case-control study. *British Journal of Clinical Pharmacology*, 58(1), 71–80.
- De Smet, P. (2002). Herbal remedies. *The New England Journal of Medicine*, 346(20), 2046–2056.
- De Smet, P. A. G. M. (2004). Health risks of herbal remedies: an update. *Clinical Pharmacology & Therapeutics*, 76(1), 1–17.
- Dehkordi, F. R., & Kamkhah, A. F. (2008). Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension. *Fundamental & Clinical Pharmacology*, 22(4), 447–452.
- Denham, A., McIntyre, M., & Whitehouse, J. (2002). Kava—the unfolding story: report on a work-in-progress. *The Journal of Alternative & Complementary Medicine*, 8(3), 237–263.
- Dentali, S. J. (2011). Herb Safety Review: kava--Piper methysticum Forster f. *Food and Chemical Toxicology*, 49(11), 2820–9.
- Di Luzio, N. R. (1966). A mechanism of the acute ethanol-induced fatty liver and the modification of liver injury by antioxidants. *American Journal of Pharmacy and the Sciences Supporting Public Health*, 15(1 Pt 1), 50–63.
- Dixon, L. J., Barnes, M., Tang, H., Pritchard, M. T., & Nagy, L. E. (2013). Kupffer cells in the liver. *Comprehensive Physiology*.
- Dollah, M. A., Parhizkar, S., Latiff, L. A., & Hassan, M. H. Bin. (2013). Toxicity effect of Nigella sativa on the liver function of rats. *Advanced Pharmaceutical Bulletin*, 3(1), 97.
- Donohue, T. M., Zetternan, R. K., & Turna, D. J. (1989). Effect of chronic ethanol administration on protein catabolism in rat liver. *Alcoholism: Clinical and Experimental Research*, 13(1), 49–57.
- Dragull, K., Yoshida, W. Y., & Tang, C.-S. (2003). Piperidine alkaloids from Piper methysticum. *Phytochemistry*, 63(2), 193–198.
- Duffield, P. H., & Jamieson, D. (1991). Development of tolerance to kava in mice. *Clinical and Experimental Pharmacology and Physiology*, 18(8), 571–578.

- Duryee, M. J., Klassen, L. W., Freeman, T. L., Willis, M. S., Tuma, D. J., & Thiele, G. M. (2004). Lipopolysaccharide Is a Cofactor for Malondialdehyde-Acetaldehyde Adduct-Mediated Cytokine/Chemokine Release by Rat Sinusoidal Liver Endothelial and Kupffer Cells. *Alcoholism: Clinical and Experimental Research*, 28(12), 1931–1938.
- Earnest, D. L., Abril, E. R., Jolly, C. S., & Eskelson, C. D. (1993). Kupffer cell function is modified by both diet and ethanol. *ADVANCES IN THE BIOSCIENCES-OXFORD-*, 86, 181.
- Ekström, G., & Ingelman-Sundberg, M. (1989). Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIIE1). *Biochemical Pharmacology*, 38(8), 1313–1319.
- El-Abhar, H. S., Abdallah, D. M., & Saleh, S. (2003). Gastroprotective activity of Nigella sativa oil and its constituent, thymoquinone, against gastric mucosal injury induced by ischaemia/reperfusion in rats. *Journal of Ethnopharmacology*, 84(2), 251–258.
- El-Dakhakhny, M., Barakat, M., El-Halim, M. A., & Aly, S. M. (2000). Effects of Nigella sativa oil on gastric secretion and ethanol induced ulcer in rats. *Journal of Ethnopharmacology*, 72(1–2), 299–304.
- El-Dakhakhny, M., Mady, N. I., & Halim, M. A. (2000). Nigella sativa L. oil protects against induced hepatotoxicity and improves serum lipid profile in rats. *Arzneimittelforschung*, 50(9), 832–836.
- El-Far, A. H., Bazh, E. K., & Moharam, M. S. (2014). Antioxidant and Antinematodal Effects of Nigella Sativa and Zingiber Officinale Supplementation in Ewes. *Int J Pharm Sci Rev Res*, 26(1), 222–227.
- El-Kholy, S. M. S., & El-Salam, S. A. (2011). Kava extract drug: what is the actual risk of hepatotoxicity in adult male albino rats? *Egyptian Journal of Histology*, 34(4), 697–704.
- El-Khouly, D., El-Bakly, W. M., Awad, A. S., El-Mesallamy, H. O., & El-Demerdash, E. (2012). Thymoquinone blocks lung injury and fibrosis by attenuating bleomycin-induced oxidative stress and activation of nuclear factor Kappa-B in rats. *Toxicology*, 302(2), 106–113.
- El-Missiry, M. A., & El Gindy, A. M. (2000). Amelioration of alloxan induced diabetes mellitus and oxidative stress in rats by oil of Eruca sativa seeds. *Annals of Nutrition and Metabolism*, 44(3), 97–100.
- El-Tahir, K., & Bakeet, D. M. (2006). The black seed Nigella sativa Linnaeus-A mine for multi cures: a plea for urgent clinical evaluation of its volatile oil. *Journal of Taibah University Medical Sciences*, 1(1), 1–19.

- El-Tawil, O., & Moussa, S. Z. (2006). Antioxidant and hepatoprotective effects of thymoquinone against carbon tetrachloride-induced hepatotoxicity in isolated rat hepatocyte. *J Egypt Soc Toxicol*, 34, 33–41.
- Ernst, E. (2002). Safety concerns about kava. *The Lancet*, 359(9320), 1865.
- Ernst, E. (2006). Herbal remedies for anxiety--a systematic review of controlled clinical trials. *Phytomedicine*, 13(3), 205–208.
- Escher, M., Desmeules, J., Giostra, E., & Mentha, G. (2001). Hepatitis associated with Kava, a herbal remedy for anxiety. *British Medical Journal*, 322(7279), 139.
- Farah, I. O. (2005). Assessment of cellular responses to oxidative stress using MCF-7 breast cancer cells, black seed (*N. Sativa L.*) extracts and H₂O₂. *International Journal of Environmental Research and Public Health*, 2(3), 411–419.
- Fernandez-Checa, J. C., & Kaplowitz, N. (2005). Hepatic mitochondrial glutathione: transport and role in disease and toxicity. *Toxicology and Applied Pharmacology*, 204(3), 263–273.
- Ferrari, C. K. B. (2004). Functional foods, herbs and nutraceuticals: towards biochemical mechanisms of healthy aging. *Biogerontology*, 5(5), 275–289.
- Folz, R. J., & Crapo, J. D. (1994). Extracellular superoxide dismutase (SOD3): tissue-specific expression, genomic characterization, and computer-assisted sequence analysis of the human EC SOD gene. *Genomics*, 22(1), 162–171.
- Fouda, A.-M. M., Daba, M.-H. Y., & Yousef Ahmed, A. R. (2014). Antigenotoxic effects of thymoquinone against benzo [a] pyrene and mitomycin C-induced genotoxicity in cultured human lymphocytes. *Research in Immunology: An International Journal*, 2014(12), 1–7.
- Fouda, A. M. A.-M. M., Daba, M.-H. Y. M. Y., Dahab, G. M., Sharaf el-Din, O. A., & Sharaf el-Din, O. A. (2008). Thymoquinone ameliorates renal oxidative damage and proliferative response induced by mercuric chloride in rats. *Basic & Clinical Pharmacology & Toxicology*, 103(2), 109–118.
- Fridovich, I. (1995). Superoxide radical and superoxide dismutases. *Annual Review of Biochemistry*, 64(1), 97–112.
- Fromm, M. F., Kroemer, H. K., & Eichelbaum, M. (1997). Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs. *Advanced Drug Delivery Reviews*, 27(2), 171–199.
- Fu, P. P., Xia, Q., Guo, L., Yu, H., & Chan, P.-C. (2008). Toxicity of kava kava. *Journal of Environmental Science and Health Part C*, 26(1), 89–112.

- Fugh-Berman, A., & Ernst, E. (2001). Herb--drug interactions: review and assessment of report reliability. *British Journal of Clinical Pharmacology*, 52(5), 587–595.
- Gaber M.G. Shehab and Hosam Eldin H. Osman. (2014). Nigella sativa seeds ameliorate the hepatotoxicity and nephrotoxicity of colchicine prolonged use in Albino Rats: a biochemical and histopathological study. *Australian Journal of Basic and Applied Sciences*, 8(2), 362–370.
- Gali-Muhtasib, H., El-Najjar, N., & Schneider-Stock, R. (2006). The medicinal potential of black seed (Nigella sativa) and its components. *Advances in Phytomedicine*, 2, 133–153.
- Gerenova, J., & Gadjeva, V. (2005). Changes in parameters of oxidative stress in patients with Graves' disease. *Trakia Journal of Sciences*, 3(4), 32–36.
- Gibson, G. G., Plant, N. J., Swales, K. E., Ayrton, A., & El-Sankary, W. (2002). Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. *Xenobiotica*, 32(3), 165–206.
- Goreja, W. G. (2003). *Black seed: nature's miracle remedy* (3rd Editio). Karger Publishers. Retrieved from <https://www.amazon.com/Black-Seed-Natures-Miracle-Remedy/dp/097429621X%0A>
- Grattagliano, I., Bonfrate, L., Diogo, C. V., Wang, H. H., Wang, D. Q. H., & Portincasa, P. (2009). Biochemical mechanisms in drug-induced liver injury: certainties and doubts. *World Journal of Gastroenterology: WJG*, 15(39), 4865.
- Grover, J. K., & Yadav, S. P. (2004). Pharmacological actions and potential uses of Momordica charantia: a review. *Journal of Ethnopharmacology*, 93(1), 123–132.
- Gruenwald, J., & Freder, J. (2002). Kava: the present European situation. *Nutraceuticals World*, 4, 22–24.
- Guo, L., Li, Q., Xia, Q., Dial, S., Chan, P.-C., & Fu, P. (2009). Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract. *Food and Chemical Toxicology*, 47(2), 433–442.
- Guo, L., Shi, Q., Dial, S., Xia, Q., Mei, N., Li, Q., ... Fu, P. (2010). Gene expression profiling in male B6C3F1 mouse livers exposed to kava identifies—Changes in drug metabolizing genes and potential mechanisms linked to kava toxicity. *Food and Chemical Toxicology*, 48(2), 686–696.
- Hafeman, D. G., Sunde, R. A., & Hoekstra, W. G. (1974). Effect of dietary selenium on erythrocyte and liver glutathione peroxidase in the rat. *The Journal of Nutrition*, 104(5), 580–587.

- Hall, A. P., Elcombe, C. R., Foster, J. R., Harada, T., Kaufmann, W., Knippel, A., ... Nishikawa, A. (2012). Liver hypertrophy: a review of adaptive (adverse and non-adverse) changes—conclusions from the 3rd International ESTP Expert Workshop. *Toxicologic Pathology*, 40(7), 971–994.
- Halliwell, B., & Gutteridge, J. M. C. (1992). Biologically relevant metal ion-dependent hydroxyl radical generation An update. *FEBS Letters*, 307(1), 108–112.
- Halliwell, B., & Gutteridge, J. M. C. (2015). *Free radicals in biology and medicine*. Oxford University Press, USA.
- Handy, E. S. (1972). *Native planters in old Hawaii* (2, illustr ed.). Bishop Museum Press,. <https://doi.org/https://trove.nla.gov.au/work/21239642>.
- Hänsel, R., & Woelk, H. (1994). Spektrum Kava-Kava. Arzneimitteltherapie heute, Phytopharmaka, Bd. 6. Aesopus Verlag, Basel.
- Haq, A., Abdullatif, M., Lobo, P. I., Khabar, K. S. A., Sheth, K. V., & Al-Sedairy, S. T. (1995). Nigella sativa: effect on human lymphocytes and polymorphonuclear leukocyte phagocytic activity. *Immunopharmacology*, 30(2), 147–155.
- Haq, A., Lobo, P. I., Al-Tufail, M., Rama, N. R., & Al-Sedairy, S. T. (1999). Immunomodulatory effect of Nigella sativa proteins fractionated by ion exchange chromatography. *International Journal of Immunopharmacology*, 21(4), 283–295.
- Hayat, M. A., & Giaquinta, R. (1970). Rapid fixation and embedding for electron microscopy. *Tissue and Cell*, 2(2), 191–195.
- He, X., Lin, L., & Lian, L. (1997). Electrospray high performance liquid chromatography-mass spectrometry in phytochemical analysis of kava (*Piper methysticum*) extract. *Planta Medica*, 63(1), 70–74.
- Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., & Lai, Eric., O. (2002). Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. *The Lancet*, 359(9312), 1121–1122.
- Hmza, A. J. A., Osman, M. T., Adnan, A., & Omar, E. (2013). Immunomodulatory effect of Nigella sativa oil in the disease process of type 1 diabetic rats. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 4(1), 980–988.
- Hodgson, E., & Philpot, R. M. (1975). Interaction of methylenedioxymethyl (1, 3-benzodioxole) compounds with enzymes and their effects on mammals. *Drug Metabolism Reviews*, 3(1), 231–301.
- Hoek, J. B. (1999). Endotoxin and alcoholic liver disease: tolerance and susceptibility. *Hepatology*, 29(5), 1602–1604.

- Holben, D. H., & Smith, A. M. (1999). The diverse role of selenium within selenoproteins: a review. *Journal of the American Dietetic Association*, 99(7), 836–843.
- Hosseinzadeh, H., Fazly Bazzaz, B. S., & Haghi, M. M. (2007). Antibacterial activity of total extracts and essential oil of *Nigella sativa* L. seeds in mice. *Pharmacologyonline*, 2, 429–435.
- Houghton, P. J., Zarka, R., de las Heras, B., & Hoult, J. R. S. (1995). Fixed oil of *Nigella sativa* and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. *Planta Medica*, 61(1), 33–36.
- Hritz, I., Velayudham, A., Dolganiuc, A., Kodys, K., Mandrekar, P., Kurt-Jones, E., & Szabo, G. (2008). Bone marrow–derived immune cells mediate sensitization to liver injury in a myeloid differentiation factor 88-dependent fashion. *Hepatology*, 48(4), 1342–1347.
- Hsu, S.-Y., Lin, M.-H., Lin, L.-C., & Chou, C.-J. (1994). Toxicologic studies of dihydro-5, 6-dehydrokawain and 5, 6-dehydrokawain. *Planta Medica*, 60(1), 88–90.
- Hu, Z., Yang, X., Ho, P. C. L., Chan, S. Y., Heng, P. W. S., & Chan, Eli., O. (2005). Herb-drug interactions. *Drugs*, 65(9), 1239–1282.
- Humberston, C. L., Akhtar, J., & Krenzelok, E. P. (2003). Acute hepatitis induced by kava kava. *Journal of Toxicology: Clinical Toxicology*, 41(2), 109–113.
- Hussain, A. R., Ahmed, M., Ahmed, S., Manogaran, P., Plataniolas, L. C., Alvi, S. N., ... Uddin, S. (2011). Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma. *Free Radical Biology and Medicine*, 50(8), 978–987.
- Hussaini, S. H., & Farrington, E. A. (2007). Idiosyncratic drug-induced liver injury: an overview. *Expert Opinion on Drug Safety*, 6(6), 673–684.
- Hussein, M. R., Abu-Dieff, E. E., Abd el-Reheem, M. H., & Abd-Elrahman, A. (2005). Ultrastructural evaluation of the radioprotective effects of melatonin against X-ray-induced skin damage in Albino rats. *International Journal of Experimental Pathology*, 86(1), 45–55.
- Iimuro, Y., Bradford, B. U., Yamashina, S., Rusyn, I., Nakagami, M., & Enomoto, Nobuyuki, O. (2000). The glutathione precursor L-2-oxothiazolidine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat. *Hepatology*, 31(2), 391–398.
- Ismail, M., Al-Nafeeq, G., & Chan, K. W. (2010). *Nigella sativa* thymoquinone-rich fraction greatly improves plasma antioxidant capacity and expression of antioxidant genes in hypercholesterolemic rats. *Free Radical Biology and Medicine*, 48(5), 664–672.

- Jamieson, D. D., & Duffield, P. H. (1990a). Positive interaction of ethanol and kava resin in mice. *Clinical and Experimental Pharmacology and Physiology*, 17(7), 509–514.
- Jamieson, D. D., & Duffield, P. H. (1990b). The antinociceptive actions of kava components in mice. *Clinical and Experimental Pharmacology and Physiology*, 17(7), 495–507.
- Jamieson, D. D., Duffield, P. H., Cheng, D., & Duffield, A. M. (1989). Comparison of the central nervous system activity of the aqueous and lipid extract of kava (*Piper methysticum*). *Archives Internationales de Pharmacodynamie et de Thérapie*, 301, 66–80.
- Johnson, B. M., Qiu, S., Zhang, S., Zhang, F., & Burdette, Joanna E., O. (2003). Identification of novel electrophilic metabolites of *Piper methysticum* Forst.(Kava). *Chemical Research in Toxicology*, 16(6), 733–740.
- Johnson, T. (1998). *CRC ethnobotany desk reference* (1st Editio). CRC Press. <https://doi.org/https://www.amazon.com/CRC-Ethnobotany-Desk-Reference-Johnson/dp/084931187X> /Medicine & Health Science Books @ Amazon.com
- Jussofie, A., Schmiz, A., & Hiemke, C. (1994). Kavapyrone enriched extract from *Piper methysticum* as modulator of the GABA binding site in different regions of rat brain. *Psychopharmacology*, 116(4), 469–474.
- Kakkar, R., Mantha, S. V, Radhi, J., Prasad, K., & Kalra, J. (1997). Antioxidant defense system in diabetic kidney: a time course study. *Life Sciences*, 60(9), 667–679.
- Kaleem, M., Kirmani, D., Asif, M., Ahmed, Q., & Bano, B. (2006). Biochemical effects of *Nigella sativa* L seeds in diabetic rats.
- Kalpana, P., Rao, A., Saraswathi, G., & Srinivasan, K. (2002). Digestive stimulant action of three Indian spice mixes in experimental rats. *Food/Nahrung*, 46(6), 394–398.
- Kang, S.M., Maeda, K., Onoda, N., Chung, Y.S., Nakata, B., Nishiguchi, Y., & Sowa, M. (2004). Role of oxidative stress in the etiology of type 2 diabetes and the effect of antioxidant supplementation on glycemic control. *Journal of Investigative Medicine*, 52(1), 19–23.
- Kang, S.-M., Maeda, K., Onoda, N., Chung, Y.-S., Nakata, B., Nishiguchi, Y., & Sowa, M. (1997). Combined analysis of p 53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. *International Journal of Cancer*, 74(5), 502–507.

- Kanter, M., Meral, I., Dede, S., Cemek, M., Ozbek, H., Uygan, I., & Gunduz, H. (2003). Effects of *Nigella sativa* L. and *Urtica dioica* L. on lipid peroxidation, antioxidant enzyme systems and some liver enzymes in CCl₄-treated rats. *Transboundary and Emerging Diseases*, 50(5), 264–268.
- Kaplowitz, N. (1997). Hepatotoxicity of herbal remedies: insights into the intricacies of plant-animal warfare and cell death. *Gastroenterology*, 113(4), 1408–1412.
- Kaplowitz, N. (2000). Mechanisms of liver cell injury. *Journal of Hepatology*, 32, 39–47.
- Kaplowitz, N. (2001). Causality assessment versus guilt-by-association in drug hepatotoxicity. *Hepatology*, 33(1), 308–310.
- Kaplowitz, N. (2002). Biochemical and cellular mechanisms of toxic liver injury. In *Seminars in liver disease* (Vol. 22, pp. 137–144).
- Kataria, N., Kataria, A. K., Pandey, N., & Gupta, P. (2010). Serum biomarkers of physiological defense against reactive oxygen species during environmental stress in Indian dromedaries. *Human & Veterinary Medicine*, 2(2), 55–58.
- Kaufman, M. H. (1983). Ethanol-induced chromosomal abnormalities at conception. *Nature*, 302(5905), 258–260.
- Keledjian, J., Duffield, P. H., Jamieson, D. D., Lidgard, R. O., & Duffield, A. M. (1988). Uptake into mouse brain of four compounds present in the psychoactive beverage kava. *Journal of Pharmaceutical Sciences*, 77(12), 1003–1006.
- Khader, M., Bresgen, N., & Eckl, P. M. (2009). In vitro toxicological properties of thymoquinone. *Food and Chemical Toxicology*, 47(1), 129–133.
- Khader, M., Eckl, P. M., & Bresgen, N. (2007). Effects of aqueous extracts of medicinal plants on MNNG-treated rat hepatocytes in primary cultures. *Journal of Ethnopharmacology*, 112(1), 199–202.
- Khalife, K. H., & Lupidi, G. (2008). Reduction of hypervalent states of myoglobin and hemoglobin to their ferrous forms by thymoquinone: the role of GSH, NADH and NADPH. *Biochimica et Biophysica Acta (BBA)-General Subjects*, 1780(4), 627–637.
- Khan, A., Chen, H. C., Tania, M., & Zhang, Dian Zheng, O. (2011). Anticancer activities of *Nigella sativa* (black cumin). *African Journal of Traditional, Complementary and Alternative Medicines*, 8(5), 226–232. <https://doi.org/10.4314/ajtcam.v8i5S.10>
- Khan, M. A., & Afzal, M. (2016). Chemical composition of *Nigella sativa* Linn: part 2 recent advances. *Inflammopharmacology*, 24(2–3), 67–79.

- Khatri, V. (2011). *Effect of Aspirin Intervention on Platelet Aggregation In Non-Kava Drinking and Kava Drinking Fijian and Indo-Fijian Healthy Volunteers and Determination of Aspirin Resistance*. Retrieved from (Doctoral dissertation, Ph.D. Thesis, Faculty of Science, Technology and Environment, University of South Pacific, Fiji Islands).
- Kim, M. S., & Akera, T. (1987). O₂ free radicals: cause of ischemia-reperfusion injury to cardiac Na⁺-K⁺-ATPase. *American Journal of Physiology-Heart and Circulatory Physiology*, 252(2), H252--H257.
- Kindmark, A., Jawaid, A., Harbron, C. G., Barratt, B. J., Bengtsson, O. F., Andersson, T. B., & Carlsson, S., O. (2008). Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. *The Pharmacogenomics Journal*, 8(3), 186–195.
- Klassen, L. W., Tuma, D., & Sorrell, M. F. (1995). Immune mechanisms of alcohol-induced liver disease. *Hepatology*, 22(1), 355–357.
- Klebanoff, S. J. (1968). Myeloperoxidase-halide-hydrogen peroxide antibacterial system. *Journal of Bacteriology*, 95(6), 2131–2138.
- Klohs, M. W. (1967). Chemistry of kava. *Psychopharmacology Bulletin*, 4(3), 10.
- Koch, O. R., Pani, G., Borrello, S., Colavitti, R., Cravero, A., Farrè, S., & Galeotti, T. (2004). Oxidative stress and antioxidant defenses in ethanol-induced cell injury. *Molecular Aspects of Medicine*, 25(1–2), 191–198.
- Kohen, R., & Nyska, A. (2002). Invited review: Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. *Toxicologic Pathology*, 30(6), 620–650.
- Koivisto, T., Mishin, V. M., Mak, K. M., Cohen, P. A., & Lieber, C. S. (1996). Induction of cytochrome P-4502E1 by ethanol in rat Kupffer cells. *Alcoholism: Clinical and Experimental Research*, 20(2), 207–212.
- Kolios, G., Valatas, V., & Kouroumalis, E. (2006). Role of Kupffer cells in the pathogenesis of liver disease. *World Journal of Gastroenterology: WJG*, 12(46), 7413.
- Kono, H., Bradford, B. U., Yin, M., Sulik, K. K., Koop, D. R., & Peters, J., O. (1999). CYP2E1 is not involved in early alcohol-induced liver injury. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 277(6), G1259–G1267.
- Kono, H., Rusyn, I., Bradford, B. U., Connor, H. D., Mason, R. P., & Thurman, R. G. (2000). Allopurinol prevents early alcohol-induced liver injury in rats. *Journal of Pharmacology and Experimental Therapeutics*, 293(1), 296–303.

- Kovacic, P., & Somanathan, R. (2012). Redox processes in neurodegenerative disease involving reactive oxygen species. *Current Neuropharmacology*, 10(4), 289–302.
- Kraft, M., Spahn, T. W., Menzel, J., Senninger, N., Dietl, K. H., Herbst, H., ... Lerch, M. M. (2001). Fulminant liver failure after administration of the herbal antidepressant Kava-Kava. *Deutsche Medizinische Wochenschrift* (1946), 126(36), 970–972.
- Kroemer, G., & Reed, J. C. (2000). Mitochondrial control of cell death. *Nature Medicine*, 6(5), 513.
- Kruk, I., Michalska, T., Lichszteld, K., Kładna, A., & Aboul-Enein, H. Y. (2000). The effect of thymol and its derivatives on reactions generating reactive oxygen species. *Chemosphere*, 41(7), 1059–1064.
- Kumar, V. (2006). Potential medicinal plants for CNS disorders: an overview. *Phytotherapy Research*, 20(12), 1023–1035.
- Landa, P., Marsik, P., Havlik, J., Kloucek, P., Vanek, T., & Kokoska, L. (2009). Evaluation of antimicrobial and anti-inflammatory activities of seed extracts from six Nigella species. *Journal of Medicinal Food*, 12(2), 408–415.
- Lapenna, D., Ciofani, G., Pierdomenico, S. D., Giamberardino, M. A., & Cuccurullo, F. (2001). Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxidation in human plasma. *Free Radical Biology and Medicine*, 31(3), 331–335.
- Lawrence, R. A., & Burk, R. F. (1976). Glutathione peroxidase activity in selenium-deficient rat liver. *Biochemical and Biophysical Research Communications*, 71(4), 952–958.
- Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *Journal of the American Medical Association*, 279(15), 1200–1205.
- Lebot, V. (1989). L'histoire du kava commence par sa découverte. *Journal de La Société Des Océanistes*, 88(1), 89–114. <https://doi.org/10.3406/jso.1989.2855>
- Lebot, V., Merlin, M., & Lindstrom, L. (1997). *Kava: The Pacific elixir: The definitive guide to its ethnobotany, history, and chemistry*. Inner Traditions/Bear & Co.
- Lebot, V., Merlin, M., Lindstrom, L., & others. (1992). *Kava: the Pacific drug*. (1st editio). Yale University Press.
- Lee, C.-P., Shih, P.-H., Hsu, C.-L., & Yen, G.-C. (2007). Hepatoprotection of tea seed oil (*Camellia oleifera* Abel.) against CCl₄-induced oxidative damage in rats. *Food and Chemical Toxicology*, 45(6), 888–895.

- Lee, W. M. (2003). Drug-induced hepatotoxicity. *New England Journal of Medicine*, 349(5), 474–485.
- Leong, X.-F., Rais Mustafa, M., & Jaarin, K. (2013). Nigella sativa and its protective role in oxidative stress and hypertension. *Evidence-Based Complementary and Alternative Medicine*, 2013.
- Lettéron, P., Fromenty, B., Beno, T., Degott, C., & Pessayre, D. (1996). Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. *Journal of Hepatology*, 24(2), 200–208.
- Lieber, C. S. (1988). Metabolic effects of acetaldehyde. *Biochemical Society Transactions*, 16(3), 241–247.
- Lieber, C. S. (2004). Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. *Alcohol*, 34(1), 9–19. <https://doi.org/10.1016/j.alcohol.2004.07.008>
- Lim, S. T. S. (2006). *Kava-associated Hepatotoxicity*. Retrieved from (Master dissertation. Thesis, Faculty of Molecular Biosciences And Bioengineering, University of Hawaii At Manoa.
- Limdi, J. K., & Hyde, G. M. (2003). Evaluation of abnormal liver function tests. *Postgraduate Medical Journal*, 79(932), 307–312.
- Liu, R.-M., & Choi, J. (2000). Age-associated decline in gamma-glutamylcysteine synthetase gene expression in rats. *Free Radical Biology and Medicine*, 28(4), 566–574.
- Liu, Z.-X., & Kaplowitz, N. (2002). Immune-mediated drug-induced liver disease. *Clinics in Liver Disease*, 6(3), 755–774.
- Lüde, S. (2005). *Hepatotoxicity of the phytomedicines Kava kava and Cimicifuga racemosa*. Retrieved from (Doctoral dissertation, Ph.D. Thesis, Faculty of Philosophical Sciences and Natural Sciences, University of Basel, Switzerland).
- Ma, K. L., Ruan, X. Z., Powis, S. H., Chen, Y., Moorhead, J. F., & Varghese, Z. (2008). Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. *Hepatology*, 48(3), 770–781.
- Maddrey, W. C. (2002). *Clinicopathological patterns of drug-induced liver disease. Drug-induced liver disease* (3rd Editio). CRC Press. Retrieved from https://www.researchgate.net/.../Clinicopathological-Patterns-of-DILI_tbl4_303040946
- Maher, J. (2001). The CYP2E1 knockout delivers another punch: first ASH, now NASH. *Hepatology*, 33(1), 311–312.

- Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore, C., & Sayer, D., O. (2002). Association between presence of HLA-B* 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *The Lancet*, 359(9308), 727–732.
- Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., & Tomažič, Janez, O. (2008). HLA-B* 5701 screening for hypersensitivity to abacavir. *New England Journal of Medicine*, 358(6), 568–579.
- Mandrekar, P., & Szabo, G. (2009). Signalling pathways in alcohol-induced liver inflammation. *Journal of Hepatology*, 50(6), 1258–1266.
- Mansour, M. A., Ginawi, O. T., El-Hadiyah, T., El-Khatib, A. S., Al-Shabanah, O. A., & Al-Sawaf, H. A. (2001). Effects of volatile oil constituents of Nigella sativa on carbon tetrachloride-induced hepatotoxicity in mice: evidence for antioxidant effects of thymoquinone. *Research Communications in Molecular Pathology and Pharmacology*, 110(3–4), 239–252.
- Mansour, M. A., Nagi, M. N., El-Khatib, A. S., Al-Bekairi, A. M., El-Khatib, A. S., & Al-Bekairi, A. M. (2002). Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT-diaphorase in different tissues of mice: a possible mechanism of action. *Cell Biochemistry and Function*, 20(2), 143–151.
- Marklund, S. L. (1984). Extracellular superoxide dismutase and other superoxide dismutase isoenzymes in tissues from nine mammalian species. *Biochemical Journal*, 222(3), 649–655.
- Maronpot, R. R., Yoshizawa, K., Nyska, A., Harada, T., Flake, G., Mueller, G., ... Ward, J. M. (2010). Hepatic enzyme induction: histopathology. *Toxicologic Pathology*, 38(5), 776–795.
- Masters, C. J. (1996). Cellular signalling: the role of the peroxisome. *Cellular Signalling*, 8(3), 197–208.
- Mathews, J. D., Riley, M. D., Fejo, L., Munoz, E., Milns, N. R., & Gardner, Ian D., O. (1988). Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. *The Medical Journal of Australia*, 148(11), 548–555.
- Mathews, J. M., Etheridge, A. S., & Black, S. R. (2002). Inhibition of human cytochrome P450 activities by kava extract and kavalactones. *Drug Metabolism and Disposition*, 30(11), 1153–1157.
- Mathews, J. M., Etheridge, A. S., Valentine, J. L., Black, S. R., & Coleman, Donna P., O. (2005). Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. *Drug Metabolism and Disposition*, 33(10), 1555–1563.

- McCord, J. M., & Fridovich, I. (1969). Superoxide dismutase an enzymic function for erythrocuprein (hemocuprein). *Journal of Biological Chemistry*, 244(22), 6049–6055.
- Meijerman, I., Beijnen, J. H., & Schellens, J. H. M. (2006). Herb-drug interactions in oncology: focus on mechanisms of induction. *The Oncologist*, 11(7), 742–752.
- Meral, I., Yener, Z., Kahraman, T., & Mert, N. (2001). Effect of *Nigella sativa* on glucose concentration, lipid peroxidation, anti-oxidant defence system and liver damage in experimentally-induced diabetic rabbits. *Transboundary and Emerging Diseases*, 48(10), 593–599.
- Meziti, A., Meziti, H., Boudiaf, K., Mustapha, B., & Bouriche, H. (2012). Polyphenolic profile and antioxidant activities of *Nigella sativa* seed extracts in vitro and in vivo. *World Academy of Science, Engineering and Technology*, 64(6), 24–32.
- Miguel, M. G. (2010). Antioxidant and anti-inflammatory activities of essential oils: a short review. *Molecules*, 15(12), 9252–9287.
- Miller, L. G. (1998). Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. *Archives of Internal Medicine*, 158(20), 2200–2211.
- Mills, S., Bone, K., & others. (2000). *Principles and practice of phytotherapy. Modern herbal medicine*. (2nd Editio). USA: Churchill Livingstone.
- Mobley, J. A., & Brueggemeier, R. W. (2004). Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. *Carcinogenesis*, 25(1), 3–9.
- Mohamed, A., Afridi, D. M., Garani, O., & Tucci, M. (2004). Thymoquinone inhibits the activation of NF-kappaB in the brain and spinal cord of experimental autoimmune encephalomyelitis. *Biomedical Sciences Instrumentation*, 41, 388–393.
- Mohamed, A. H., El-Saidy, B. E., & El-Seidy, I. A. (2003). Influence of some medicinal plants supplementation: 1-On digestibility, nutritive value, rumen fermentation and some blood biochemical parameters in sheep. *Egyptian Journal of Nutrition and Feeds*, 6(2), 139–150.
- Mollazadeh, H., & Hosseinzadeh, H. (2014). The protective effect of *Nigella Sativa* against liver injury: a review. *Iranian Journal of Basic Medical Sciences*, 17(12), 958.
- Moore, T. J., Cohen, M. R., & Furberg, C. D. (2007). Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. *Archives of Internal Medicine*, 167(16), 1752–1759.

- Moulds, R. F. W., & Malani, J. (2003). Kava: herbal panacea or liver poison? *The Medical Journal of Australia*, 178(9), 451–453.
- Murray, R. K., Granner, D. K., Mayes, P. A., & Rodwell, V. W. (2014). *Harper's illustrated biochemistry*. McGraw-Hill. <https://doi.org/3rd Edition>, 321-375.
- Musa, D., Dilsiz, N., Gumushan, H., Ulakoglu, G., & Bitiren, M. (2004). Antitumor activity of an ethanol extract of *Nigella sativa* seeds. *Biologia, Bratislava*, 59(6), 735–740.
- Nagi, M. N., Alam, K., Badary, O. A., Al-Shabanah, O. A., Al-Sawaf, H. A., & Al-Bekairi, A. M. (1999). Thymoquinone protects against carbon tetrachloride hepatotoxicity in mice via an antioxidant mechanism. *International Union of Biochemistry and Molecular Biology*, 47(1), 153–159.
- Nagi, M. N., & Almakki, H. A. (2009). Thymoquinone supplementation induces quinone reductase and glutathione transferase in mice liver: possible role in protection against chemical carcinogenesis and toxicity. *Phytotherapy Research*, 23(9), 1295–1298.
- Nagi, M. N., Almakki, H. A., Sayed-Ahmed, M. M., & Al-Bekairi, A. M. (2010). Thymoquinone supplementation reverses acetaminophen-induced oxidative stress, nitric oxide production and energy decline in mice liver. *Food and Chemical Toxicology*, 48(8–9), 2361–2365.
- Nagi, M. N., & Mansour, M. A. (2000). Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. *Pharmacological Research*, 41(3), 283–289.
- Nanji, A. A. (2004). Role of different dietary fatty acids in the pathogenesis of experimental alcoholic liver disease. *Alcohol*, 34(1), 21–25.
- Naranjo, C. A., Bustó, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., & others. (1981). A method for estimating the probability of adverse drug reactions. *Clinical Pharmacology and Therapeutics*, 30, 239–245.
- Narayananpillai, S. C., Leitzman, P., O'Sullivan, M. G., & Xing, C. (2014). Flavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice. *Chemical Research in Toxicology*, 27(10), 1871–1876.
- Navarro, V. J., & Senior, J. R. (2006). Drug-related hepatotoxicity. *New England Journal of Medicine*, 354(7), 731–739.
- Nergiz, C., & Ötleks, S. (1993). Chemical composition of *Nigella sativa* L. seeds. *Food Chemistry*, 48(3), 259–261.
- Newell, W. H. (1947). The kava ceremony in Tonga. *The Journal of the Polynesian Society*, 56(4), 364–417.

- Nicolson, G. L. (1982). Cancer metastasis: Organ colonization and the cell-surface properties of malignant cells. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 695(2), 113–176.
- Niemelä, O. (2001). Distribution of ethanol-induced protein adducts in vivo: Relationship to tissue injury 1, 2. *Free Radical Biology and Medicine*, 31(12), 1533–1538.
- Nili-Ahmabadi, A., Tavakoli, F., Hasanzadeh, G. R., Rahimi, H. R., & Sabzevari, O. (2011). Protective effect of pretreatment with thymoquinone against Aflatoxin B1 induced liver toxicity in mice. *Daru: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences*, 19(4), 282.
- Norris, W., Paredes, A. H., & Lewis, J. H. (2008). Drug-induced liver injury in 2007. *Current Opinion in Gastroenterology*, 24(3), 287–297.
- Norton, S. A. (1998). Herbal medicines in Hawaii from tradition to convention. *Hawaii Medical Journal*, 57(1), 382–6.
- Norton, S. A., & Ruze, P. (1994). Kava dermopathy. *Journal of the American Academy of Dermatology*, 31(1), 89–97.
- Nwunaji, T. P., Mayowa, O. O., Yusoff, S. M., Bejo, S., Salisi, S., & Mohd, E. A. (2014). The ameliorative effect of ascorbic acid on the oxidative status, live weight and recovery rate in road transport stressed goats in a hot humid tropical environment. *Animal Science Journal*, 85(5), 611–616.
- O'Sullivan, H. M., & Lum, K. (2001). Herbal medicine on the rise: the case of awa. *Pacific Health Dialog*, 8(2), 380–387.
- Paarakh, P. M. (2010). Nigella sativa Linn.-A comprehensive review. *Indian Journal of Natural Products and Resources*, 1(4), 404–429.
- Paradis, V., Kollinger, M., Fabre, M., Holstege, A., Poynard, T., & Bedossa, P. (1997). In situ detection of lipid peroxidation by-products in chronic liver diseases. *Hepatology*, 26(1), 135–142.
- Patek, A. J. (1979). Alcohol, malnutrition, and alcoholic cirrhosis. *The American Journal of Clinical Nutrition*, 32(6), 1304–1312.
- Pfeiffer, C. C., Murphree, H. B., & Goldstein, L. (1979). Effects of kava in normal subjects and patients. *Ethnopharmacologic Search for Psychoactive Drugs*, 155–161.
- Pintea, A., Zinveliu, D., Pop, R. Al, Andrei, S., & Kiss, E. (2008). Antioxidant status in dairy cows during lactation. *Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca. Veterinary Medicine*, 63(1–2).

- Pisoschi, A. M., & Pop, A. (2015). The role of antioxidants in the chemistry of oxidative stress: A review. *European Journal of Medicinal Chemistry*, 97, 55–74.
- Pittler, M. H., & Ernst, E. (2000). Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. *Journal of Clinical Psychopharmacology*, 20(1), 84–89.
- Pittler, M. H., & Ernst, E. (2003). Kava extract versus placebo for treating anxiety. *The Cochrane Library*.
- Pittler, M. H., & Ernst, E. (2003). Systematic review: hepatotoxic events associated with herbal medicinal products. *Alimentary Pharmacology & Therapeutics*, 18(5), 451–471.
- Polavarapu, R., Spitz, D. R., Sim, J. E., Follansbee, M. H., Oberley, L. W., Rahemtulla, A., & Nanji, A. A. (1998). Increased lipid peroxidation and impaired antioxidant enzyme function is associated with pathological liver injury in experimental alcoholic liver disease in rats fed diets high in corn oil and fish oil. *Hepatology*, 27(5), 1317–1323.
- Program, N. T. (2012). Toxicology and carcinogenesis studies of kava kava extract (CAS No. 9000-38-8) in F344/N rats and B6C3F1 mice (Gavage Studies). *National Toxicology Program Technical Report Series*, (571), 1.
- Raghunandhakumar, S., Paramasivam, A., Senthilraja, S., Naveenkumar, C., Asokkumar, S., Binuclara, J., ... Anandakumar, Pandi, O. (2013). Thymoquinone inhibits cell proliferation through regulation of G1/S phase cell cycle transition in N-nitrosodiethylamine-induced experimental rat hepatocellular carcinoma. *Toxicology Letters*, 223(1), 60–72.
- Rahmani, A. H., & Aly, S. M. (2015). Nigella sativa and its active constituents thymoquinone shows pivotal role in the diseases prevention and treatment. *Asian J Pharm Clin Res*, 8(1), 48–53.
- Ramadan, M. F., Kroh, L. W., & Mörsel, J.-T. (2003). Radical scavenging activity of black cumin (*Nigella sativa* L.), coriander (*Coriandrum sativum* L.), and niger (*Guizotia abyssinica* Cass.) crude seed oils and oil fractions. *Journal of Agricultural and Food Chemistry*, 51(24), 6961–6969.
- Ramana, K. V., Srivastava, S., & Singhal, S. S. (2014). Lipid peroxidation products in human health and disease 2014. *Oxidative Medicine and Cellular Longevity*, 2014.
- Rasmussen, A. K., Scheline, R. R., Solheim, E., & Hänsel, R. (1979). Metabolism of some kava pyrones in the rat. *Xenobiotica*, 9(1), 1–16.

- Raucy, J. L. (2003). Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. *Drug Metabolism and Disposition*, 31(5), 533–539.
- Ravichandiran, V., Patil Vishal, S., & Shanmugarajan, T. S. (2015). INTERNATIONAL RESEARCH JOURNAL OF PHARMACY.
- Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. (n.d.).
- Rodriguez, L. A. G., Ruigómez, A., & Jick, H. (1997). A Review of Epidemiologic Research on Drug-Induced Acute Liver Injury Using the General Practice Research Data Base in the United Kingdom. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 17(4), 721–728.
- Rolla, R., Vay, D., Mottaran, E., Parodi, M., Traverso, N., Aricó, S., Sartori, M., & Bellomo, G. O. (2000). Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease. *Hepatology*, 31(4), 878–884.
- Rowe, A., Zhang, L. Y., & Ramzan, I. (2011). Toxicokinetics of kava. *Advances in Pharmacological Sciences*, 2011.
- Russmann, S., Barguil, Y., Cabalion, P., Kritsanida, M., Duhet, D., & Lauterburg, B. H. (2003). Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. *European Journal of Gastroenterology & Hepatology*, 15(9), 1033–1036.
- Russmann, S., Lauterburg, B. H., Barguil, Y., Choblet, E., Cabalion, P., Rentsch, K., & Wenk, M. (2005). Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: Protective effect against environmental carcinogens? *Clinical Pharmacology & Therapeutics*, 77(5), 453–454.
- Russmann, S., Lauterburg, B. H., & Helbling, A. (2001). Kava hepatotoxicity. *Annals of Internal Medicine*, 135(1), 68.
- Ruze, P. (1990). Kava-induced dermatopathy: a niacin deficiency? *The Lancet*, 335(8703), 1442–1445.
- Saalu, L. C., Ogunlade, B., Ajayi, G. O., Oyewopo, A. O., Akunna, G. G., & Ogunmodede, O. S. (2012). The hepato-protective potentials of Moringa oleifera leaf extract on alcohol-induced hepato-toxicity in wistar rat. *Am J Biotechnol Mol Sci*, 2(1), 6–14.
- Salem, M. L. (2005). Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. *International Immunopharmacology*, 5(13), 1749–1770.
- Salmon, A. B., Richardson, A., & Pérez, V. I. (2010). Update on the oxidative stress theory of aging: does oxidative stress play a role in aging or healthy aging? *Free Radical Biology and Medicine*, 48(5), 642–655.

- Sampey, B. P., Korourian, S., Ronis, M. J., Badger, T. M., & Petersen, D. R. (2003). Immunohistochemical Characterization of Hepatic Malondialdehyde and 4-Hydroxyneonal Modified Proteins During Early Stages of Ethanol-Induced Liver Injury. *Alcoholism: Clinical and Experimental Research*, 27(6), 1015–1022.
- Sazuka, Y., Tanizawa, H., & Takino, Y. (1989). Effect of adriamycin on the activities of superoxide dismutase, glutathione peroxidase and catalase in tissues of mice. *Cancer Science*, 80(1), 89–94.
- Schaffert, C. S., Duryee, M. J., Hunter, C. D., Hamilton, B. C., DeVeny, A. L., & Hueter, M., O. (2009). Alcohol metabolites and lipopolysaccharide: Roles in the development and/or progression of alcoholic liver disease. *World Journal of Gastroenterology*, 15(10), 1209–1218. <https://doi.org/10.3748/wjg.15.1209>
- Schelosky, L., Raffauf, C., Jendroska, K., & Poewe, W. (1995). Kava and dopamine antagonism. *Journal of Neurology, Neurosurgery & Psychiatry*, 58(5), 639–640.
- Schenker, S., & Bay, M. K. (1995). Alcohol and endotoxin: another path to alcoholic liver injury? *Alcoholism: Clinical and Experimental Research*, 19(5), 1364–1366.
- Schmidt, M. (2003). Is kava really hepatotoxic. *Online at: Http://www.Unimuenster.De/chemie/pb/kava/analyse.Html*.
- Schmidt, M., Nahrstedt, A., & Lüpke, N. P. (2001). Piper methysticum (kava) under discussion: observations on quality, effectiveness and safety. *Wiener Medizinische Wochenschrift* (1946), 152(15–16), 382–388.
- Seif, H. S. A. (2014). Ameliorative effect of pumpkin oil (*Cucurbita pepo* L.) against alcohol-induced hepatotoxicity and oxidative stress in albino rats. *Beni-Suef University Journal of Basic and Applied Sciences*, 3(3), 178–185.
- Seven, A., GÃ¼zel, S., Seymen, O., Civelek, S., & Uncu, M. (2004). Effects of vitamin E supplementation on oxidative stress in streptozotocin induced diabetic rats: investigation of liver and plasma. *Yonsei Medical Journal*, 45(4), 703–710.
- Sgro, C., Clinard, F., Ouazir, K., Chanay, H., Allard, C., & Guilleminet, Christian, O. (2002). Incidence of drug-induced hepatic injuries: a French population-based study. *Hepatology*, 36(2), 451–455.
- Shafiq, H., Ahmad, A., Masud, T., & Kaleem, M. (2014). Cardio-protective and anti-cancer therapeutic potential of *Nigella sativa*. *Iranian Journal of Basic Medical Sciences*, 17(12), 967.

- Shaw, S., Jayatilleke, E., Ross, W. A., Gordon, E. R., & Lieber, C. S. (1981). Ethanol-induced lipid peroxidation: potentiation by long-term alcohol feeding and attenuation by methionine. *The Journal of Laboratory and Clinical Medicine*, 98(3), 417–424.
- Shoieb, A. M., Elgayyar, M., Dudrick, P. S., Bell, J. L., & Tithof, P. K. (2003). In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. *International Journal of Oncology*, 22(1), 107–113.
- Showman, A. F., Baker, J. D., Linares, C., Naeole, C. K., Borris, R., & Johnston, E., O. (2015). Contemporary Pacific and Western perspectives onawa (*Piper methysticum*) toxicology. *Fitoterapia*, 100, 56–67.
- Shulgin, A. T. (1973). The narcotic pepper: the chemistry and pharmacology of *Piper methysticum* and related species. *Bulletin on Narcotics Journals*, 25(2), 59–74.
- Siegel, R. K. (1976). Herbal intoxication: Psychoactive effects from herbal cigarettes, tea, and capsules. *Journal of the American Medical Association*, 236(5), 473–476.
- Signorini, C., Leoncini, S., De Felice, C., Pecorelli, A., Meloni, I., & Ariani, Francesca., et al. (2014). Redox imbalance and morphological changes in skin fibroblasts in typical Rett syndrome. *Oxidative Medicine and Cellular Longevity*, 2014.
- Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., ... Czaja, M. J. (2009). Autophagy regulates lipid metabolism. *Nature*, 458(7242), 1131.
- Singh, Y. N. (1992). Kava: an overview. *Journal of Ethnopharmacology*, 37(1), 13–45.
- Singh, Y. N. (2005). Potential for interaction of kava and St. John's wort with drugs. *Journal of Ethnopharmacology*, 100(1), 108–113.
- Singh, Y. N., & Devkota, A. K. (2003). Aqueous kava extracts do not affect liver function tests in rats. *Planta Medica*, 69(6), 496–499.
- Singh, Y. N., & Singh, N. N. (2002). Therapeutic potential of kava in the treatment of anxiety disorders. *CNS Drugs*, 16(11), 731–743.
- Slater, T. F. (1984). Overview of methods used for detecting lipid peroxidation. *Methods in Enzymology*, 105, 283–293.
- Sorrentino, L., Capasso, A., & Schmidt, M. (2006). Safety of ethanolic kava extract: Results of a study of chronic toxicity in rats. *Phytomedicine*, 13(8), 542–549.

- Sreejayan, N., & von Ritter, C. (1999). Lipid peroxidation in bile: the role of hydrophobic bile acids and the effect on biliary epithelial cell function. *Pathophysiology*, 5(4), 225–232.
- Stedman, C. (2002). Herbal hepatotoxicity. In *Seminars in liver disease* (Vol. 22, pp. 195–206).
- Steiner, G. G. (2000). The correlation between cancer incidence and kava consumption. *Hawaii Medical Journal*, 59(11), 420–422.
- Steinmetz, E. F. (1960). *Piper methysticum: kava-kawa-yaqona, famous drug plant of the South Sea Islands* (1st ed.). Ann Arbor, MI, USA: E. F. Steinmetz, the University of Michigan.
- Stevinson, C., Huntley, A., & Ernst, E. (2002). A systematic review of the safety of kava extract in the treatment of anxiety. *Drug Safety*, 25(4), 251–261.
- Stewart, S., Jones, D., & Day, C. P. (2001). Alcoholic liver disease: new insights into mechanisms and preventative strategies. *Trends in Molecular Medicine*, 7(9), 408–413.
- Stickel, F., Baumüller, H.-M., Seitz, K., Vasilakis, D., Seitz, G., Seitz, H. K., & Schuppan, D. (2003). Hepatitis induced by Kava (*Piper methysticum* rhizoma). *Journal of Hepatology*, 39(1), 62–67.
- Stickel, F., Patsenker, E., & Schuppan, D. (2005). Herbal hepatotoxicity. *Journal of Hepatology*, 43(5), 901–910.
- Strahl, S., Ehret, V., Dahm, H. H., & Maier, K. P. (1998). Necrotizing hepatitis after taking herbal remedies. *Deutsche Medizinische Wochenschrift* (1946), 123(47), 1410–1414.
- Szabo, G., & Bala, S. (2010). Alcoholic liver disease and the gut-liver axis. *World Journal of Gastroenterology: WJG*, 16(11), 1321.
- Takahashi, K., & Cohen, H. J. (1986). Selenium-dependent glutathione peroxidase protein and activity: immunological investigations on cellular and plasma enzymes. *Blood*, 68(3), 640–645.
- Tavakkoli, A., Ahmadi, A., Razavi, B. M., & Hosseinzadeh, H. (2017). Black seed (*Nigella sativa*) and its constituent thymoquinone as an antidote or a protective agent against natural or chemical toxicities. *Iranian Journal of Pharmaceutical Research*, 16, 2–23.
- Teschke, R., Gaus, W., & Loew, D. (2003). Kava extracts: safety and risks including rare hepatotoxicity. *Phytomedicine*, 10(5), 440–446.

- Teschke, R., & Schulze, J. (2010). Risk of kava hepatotoxicity and the FDA consumer advisory. *Journal of the American Medical Association*, 304(19), 2174–2175.
- Thiele, G. M., Worrall, S., Tuma, D. J., Klassen, L. W., Wyatt, T. A., & Nagata, N. (2001). The Chemistry and Biological Effects of Malondialdehyde-Acetaldehyde Adducts. *Alcoholism: Clinical and Experimental Research*, 25(s1).
- Thompson, R., Ruch, W., & Hasenöhrl, R. U. (2004). Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava). *Human Psychopharmacology: Clinical and Experimental*, 19(4), 243–250.
- Thomsen, M., Vitetta, L., Schmidt, M., & Sali, A. (2004). Fatal fulminant hepatic failure induced by a natural therapy containing kava (Letter to the Editor). *Medical Journal of Australia*, 180(4), 198–199.
- Thurman, R. G. (1998). Alcoholic liver injury involves activation of Kupffer cells by endotoxin. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 275(4), G605–G611.
- Tsao, P. S., Heidary, S., Wang, A., Chan, J. R., Reaven, G. M., & Cooke, J. P. (1998). Protein kinase C-epsilon mediates glucose-induced superoxide production and MCP-1 expression in endothelial cells. In *Federation of American Societies for Experimental Biology* (Vol. 12, pp. A88--A88).
- Tsukamoto, H., & LU, S. C. (2001). Current concepts in the pathogenesis of alcoholic liver injury. *The FASEB Journal*, 15(8), 1335–1349.
- Tuluce, Y., Ozkol, H., Sogut, B., & Celik, I. (2009). Effects of Nigella sativa L. on lipid peroxidation and reduced glutathione levels in erythrocytes of broiler chickens. *Cell Membranes and Free Radical Research*, 1(3), 95–99.
- Türkdo\u0111ugan, M. K., A\u0111ugao\u0111uglu, Z., Yener, Z., Sekero\u0111uglu, R., Akkan, H. A., & Avci, M. E. (2001). The role of antioxidant vitamins (C and E), selenium and Nigella sativa in the prevention of liver fibrosis and cirrhosis in rabbits: new hopes. *DTW. Deutsche Tierärztliche Wochenschrift*, 108(2), 71–73.
- Tyler, V. E., Schultz, V., & Hansel, R. (1998). Rational phytotherapy. Springer, Berlin.
- Unger, M., Holzgrabe, U., Jacobsen, W., Cummins, C., & Benet, L. Z. (2002). Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). *Planta Medica*, 68(12), 1055–1058.
- Van Houten, B., Woshner, V., & Santos, J. H. (2006). Role of mitochondrial DNA in toxic responses to oxidative stress. *DNA Repair*, 5(2), 145–152.

- Vervaart, P., & Knight, K. R. (1996). Oxidative stress and the cell. *Clinical Biochemist Reviews*, 17, 3–16.
- Vetriselvan, S., Victor, R., Parimala, D., Arun, G., & others. (2010). Comparative evaluation of hepatoprotective activity of andrographis paniculata and Silymarin in ethanol induced hepatotoxicity in albino wistar rats. *Der Pharmacia Lettre*, 2(6), 52–59.
- Vidali, M., Hietala, J., Occhino, G., Ivaldi, A., Sutti, S., Niemelä, O., & Albano, E. (2008). Immune responses against oxidative stress-derived antigens are associated with increased circulating tumor necrosis factor-alpha in heavy drinkers. *Free Radical Biology and Medicine*, 45(3), 306–311.
- Vina, J., Borras, C., Gomez-Cabrera, M.-C., & Orr, W. C. (2006). Part of the Series: From Dietary Antioxidants to Regulators in Cellular Signalling and Gene ExpressionRole of reactive oxygen species and (phyto) oestrogens in the modulation of adaptive response to stress: Review. *Free Radical Research*, 40(2), 111–119.
- Walji, H. (1996). *Kava: Nature's Relaxant for Anxiety, Stress, and Pain* (1st ed.). USA: Hohm Press,U.S. Retrieved from https://books.google.com.my/books/about/Kava.html?id=ClYs9NBiG9AC&redir_esc=y
- Wheeler, M. D., Kono, H., Yin, M., Rusyn, I., Froh, M., & Connor, H., O. (2001). Delivery of the Cu/Zn--Superoxide dismutase gene with adenovirus reduces early alcohol-induced liver injury in rats. *Gastroenterology*, 120(5), 1241–1250.
- Wheeler, M. D., Nakagami, M., Bradford, B. U., Uesugi, T., Mason, R. P., & Connor, H., O. (2001). Overexpression of manganese superoxide dismutase prevents alcohol-induced liver injury in the rat. *Journal of Biological Chemistry*, 276(39), 36664–36672.
- Whitton, P. A., Lau, A., Salisbury, A., Whitehouse, J., & Evans, C. S. (2003). Kava lactones and the kava-kava controversy. *Phytochemistry*, 64(3), 673–679.
- Wilkinson, G. R. (2005). Drug metabolism and variability among patients in drug response. *New England Journal of Medicine*, 352(21), 2211–2221.
- Williamson, R. W., & Piddington, R. O. (1939). *Essays in Polynesian Ethnology... Edited by Ralph Piddington... With an Analysis of Recent Studies in Polynesian History by the Editor.[With Maps and a Bibliography.]* (1st ed.). Cambridge: University Press. Retrieved from admin.cambridge.org/.../anthropology/anthropology.../essays-polynesian-ethnology?...
- Wilson, E. A., & Demmig-Adams, B. (2007). Antioxidant, anti-inflammatory, and antimicrobial properties of garlic and onions. *Nutrition & Food Science*, 37(3), 178–183.

- Winkelmann, R. K., Perry, H. O., Achor, R. W. P., & Kirby, T. J. (1963). Cutaneous syndromes produced as side effects of triparanol therapy. *Archives of Dermatology*, 87(3), 372–377.
- Wondergem, R., & Davis, J. (1994). Ethanol increases hepatocyte water volume. *Alcoholism: Clinical and Experimental Research*, 18(5), 1230–1236.
- Worthen, D. R., Ghosheh, O. A., & Crooks, P. A. (1998). The in vitro anti-tumor activity of some crude and purified components of blackseed, *Nigella sativa* L. *Anticancer Research*, 18(3A), 1527–1532.
- Wu, D., & Cederbaum, A. I. (2009). Oxidative stress and alcoholic liver disease. In *Seminars in liver disease* (Vol. 29, pp. 141–154). © Thieme Medical Publishers.
- Wu, D., Yu, L., Nair, M. G., De Witt, D. L., & Ramsewak, R. S. (2002). Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from *Piper methysticum* (kava kava) roots. *Phytomedicine*, 9(1), 41–47.
- Yaman, \Ihsan, & Balikci, E. (2010). Protective effects of *Nigella sativa* against gentamicin-induced nephrotoxicity in rats. *Experimental and Toxicologic Pathology*, 62(2), 183–190.
- Yarovan, N. I. (2008). Effect of zeolites on adaptation processes in cows. *Russian Agricultural Sciences*, 34(2), 120–122.
- Yiin, S. J., & Lin, T. H. (1995). Lead-catalyzed peroxidation of essential unsaturated fatty acid. *Biological Trace Element Research*, 50(2), 167–172.
- Yip, W. W., & Burt, A. D. (2006). Alcoholic liver disease. In *Seminars in diagnostic pathology* (Vol. 23, pp. 149–160).
- Young, I. S., & Woodside, J. V. (2001). Antioxidants in health and disease. *Journal of Clinical Pathology*, 54(3), 176–186.
- Zafeer, M. F., Waseem, M., Chaudhary, S., & Parvez, S. (2012). Cadmium-induced hepatotoxicity and its abrogation by thymoquinone. *Journal of Biochemical and Molecular Toxicology*, 26(5), 199–205.
- Zhang, S., Wang, X., Qi, Z., Li, S., Li, J., Meng, J., & Wang, Y. O. (1997). Studies on the Mechanism and the Effects of Selenium and Vitamin E in the Free Radicals Metabolism of Animals with Selenium Deficiency. *Acta Veterinaria Et Zootechnica Sinica*, 28, 311–317.
- Zheng, X.-G., Kang, J.-S., Kim, H.-M., Jin, G.-Z., & Ahn, B.-Z. (2000). Naphthazarin derivatives (V): Formation of glutathione conjugate and cytotoxic activity of 2-or 6-substituted 5, 8-dimethoxy-1, 4-naphthoquinones in the presence of glutathione-S-transferase, in rat liver S-9 fraction and mouse liver perfusate. *Archives of Pharmacal Research*, 23(1), 22.

- Ziaeef, T., Moharreri, N., & Hosseinzadeh, H. (2012). Review of pharmacological and toxicological effects of *Nigella sativa* and its active constituents. *Journal of Medicinal Plants*, 2(42), 16–42.
- Zou, L., Harkey, M. R., & Henderson, G. L. (2002). Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. *Life Sciences*, 71(13), 1579–1589.
- Zou, L., Henderson, G. L., Harkey, M. R., Sakai, Y., & Li, A. (2004). Effects of kava (Kava-kava, 'Awa, Yaqona, *Piper methysticum*) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. *Phytomedicine*, 11(4), 285–294.

